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Die chronische Nierenerkrankung (CKD) stellt einen wichtigen globalen ungedeckten medizinischen 
Bedarf dar. Zu einer Vielzahl von CKD-Ursachen zählen die kristallinen Nephropathien. In diesem 
Projekt wurden die Pathogenese und Relevanz der chronischen Harnsäurekristall-Nephropathie 
untersucht. Die chronische Harnsäurekristall-Nephropathie (oder Gichtnephropathie) wird definiert 
als das Vorhandensein von Harnsäure Granulomen im Nierenmark. Dieser Befund ist häufig mit einer 
ausgedehnten Nierenvernarbung verbunden. Vor einigen Jahrzehnten bezweifelten jedoch eine Reihe 
von Veröffentlichungen die klinische Relevanz der Gichtnephropathie, und die Forschung zu diesem 
Thema stagnierte seitdem. Ein weiteres umstrittenes Untersuchungsthema ist ob die Hyperurikämie 
zu einem Fortschreiten der CKD beiträgt. Ziel meines Projekts war es, medulläre Tophi mithilfe 
moderner Untersuchungstechniken neu zu bewerten: (1) die histologischen Anomalien diagnostischer 
Nierenbiopsien in einer großen Fall-Kontroll-Studie zu charakterisieren, (2) ein zuverlässiges 
Mausmodell für die Harnsäurekristall-Nephropathie zu etablieren und um zu testen, ob 
Harnsäurekristallgranulome zur CKD-Progression beitragen, und (3) um zu testen, ob eine 
asymptomatische Hyperurikämie die bereits vorhandene CKD bei Mäusen verschlimmert. 
Unsere Fall-Kontroll-Studie hat den starken Zusammenhang zwischen Nierenfibrose und dem 
Vorhandensein von Nierenmark-Tophi festgestellt. Darüber hinaus wurden mehrere bisher 
unbekannte Korrelationen wie eine starke Assoziation von Harnsäure Tophi mit Arteriosklerose und 
Verlust der Podozytenfußfortsätze festgestellt.  
Unter Verwendung von leberspezifischen und induzierbaren Glut9 K/O Mäusen wurde ein 
hyperurikämisches Mausmodell erstellt, das bei Fütterung einer acidogenen Diät mit Inosin-
Supplementierung eine kristallinduzierte tubuläre Obstruktion und damit eine Nierenerkrankung mit 
Entzündung und Fibrose entwickelte. Innerhalb der interstitiellen Fibrose bildeten sich Harnsäure 
Kristallgranulome. 
CKD wurde in hyperurikämischen (Alb-creERT2;Glut9lox/lox) und normourikämischen (Glut9lox/lox) 
Mäusen unter Verwendung von Aristolochinsäure induziert, um festzustellen, ob eine Hyperurikämie 
ohne Kristallbildung die CKD-Progression antreibt. Es gab keinen Unterschied in der CKD-Progression, 
gemessen durch eine hochempfindliche transkutane GFR-Messung. 
Zusammenfassend kann ich sagen, dass medulläre Gichttophi mit einer ausgedehnten Nierenfibrose 
assoziiert sind. Wir haben ein Mausmodell für die granulomatöse Harnsäure Nephropathie erstellt und 
gezeigt, dass die Harnsäurekristall-Nephropathie eine CKD antreibt. Hingegen die asymptomatische 





Chronic kidney disease (CKD) represents an important global unmet medical need. To a multitude of 
CKD causes belong the crystalline nephropathies. In this project, the pathogenesis and relevance of 
chronic uric acid crystal nephropathy were investigated. Chronic uric acid crystal nephropathy (or 
gouty nephropathy) is defined as the presence of uric acid granulomas in the kideny medulla. This 
finding is often associated with extensive kidney scarring. However, a few decades ago a number of 
publications questioned the clinical relevance of gouty nephropathy, and research on the subject has 
subsequently stagnated. Another controversial research topic is whether hyperuricemia contributes 
to the progression of CKD. The aim of my project was to re-evaluate medullary tophi: (1) to characterize 
the histological abnormalities of diagnostic kidney biopsies in a large case-control study, (2) to establish 
a reliable mouse model for uric acid crystal nephropathy and to test whether uric acid crystal 
granulomas contribute to CKD progression; and (3) to test whether asymptomatic hyperuricemia 
aggravates pre-existing CKD in mice. 
Our case-control study identified a strong association between kidney fibrosis and the presence of 
kidney medullary tophi. In addition, several previously unknown correlations such as a strong 
association of uric acid tophi with arteriosclerosis and loss of podocyte foot processes were found. 
Using liver-specific and inducible Glut9 K/O mice, a hyperuricemic mouse model was created which, 
when fed an acidogenic diet with inosine supplementation, developed crystal-induced tubular 
obstruction and thus kidney disease with inflammation and fibrosis. Uric acid crystal granulomas 
formed within the interstitial fibrosis. 
CKD was induced in hyperuricemic (Alb-creERT2; Glut9lox/lox) and normouricemic (Glut9lox/lox) mice using 
aristolochic acid to determine whether non-crystalline hyperuricemia drives CKD progression. There 
was no difference in CKD progression as measured by a highly sensitive transcutaneous GFR 
measurement. 
In summary, we concluded that medullary gouty tophi are associated with extensive kidney fibrosis. 
We created a mouse model of granulomatous uric acid nephropathy and showed that uric acid crystal 
nephropathy drives CKD. In contrast, asymptomatic hyperuricemia without crystalluria neither causes 
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1.1 Chronic Kidney Disease 
Chronic kidney disease (CKD) is defined as a change of kidney structure leading to organ dysfunction 
lasting for a prolonged period. According to the Kidney Disease Improving Global Outcomes (KDIGO) 
initiative, a person has CKD either if he/she, over a course of at least three months, has a glomerular 
filtration rate (GFR) below 60 ml/min/1.73 m2 or if two or more makers of kidney damage (e.g. 
albuminuria or sediment abnormalities) are present. The KDIGO classifies CKD based on both GFR and 
severity of albuminuria. Together, these markers are effective tools for predicting CKD outcomes and 
the likelihood of progression to kidney failure (Table 1) [1]. 
Table 1. KDIGO classification of CKD 
As albuminuria progresses and GFR declines, the risk of progression of GFR increases. The risk of an unfortunate 
outcome, which includes cardiovascular mortality relatively quantified in this table from 1 to 4 and color coded 
(green = little to no risk, red = high risk). Modified after [1].  
   
Albuminuria (mg albumin / g creatinine) 
   
<30 33-300 >300 
GFR 
(ml/min/1.73m2) 
>90 G1 1 1 2 
60-89 G2 1 1 2 
45-59 G3a 1 2 3 
30-44 G3b 2 3 3 
15-29 G4 3 3 4 
<15 G5 4 4 4 
 
The average human kidney is composed of around 900,000 nephrons at the time of birth, although 
there is great interindividual variance. After the development of the kidney is completed, at the 36th 
week of gestation, no new nephrons are created [2]. The GFR of a single nephron can be calculated by 
dividing the total GFR by the total number of nephrons. The single-nephron GFR averages around 80 
ml/min. An increased single-nephron GFR is associated with glomerular hypertrophy, more 




risk of CKD progression displayed in Table 1 can be explained by increases in single-nephron GFR. At 
the beginning of a kidney disease, the total GFR can be unchanged or even elevated as nephrons 
increase their single-nephron GFR by hyperfiltration [4]. This causes the glomerular shear stress in 
these remaining nephrons, which leads to accelerated podocyte loss and secondary focal segmental 
glomerulosclerosis (FSGS), causing global glomerulosclerosis and augmenting nephron loss. This 
process is a vicious cycle that leads to the progressive loss of nephrons and the decline of GFR [3]. 
When many nephrons are lost, CKD progresses to kidney failure. Kidney failure is defined as irreversible 
kidney failure that requires kidney replacement therapy (KRT), which can come in the form of 
peritoneal dialysis (PD), hemodialysis (HD), or kidney transplantation [5]. 
 
Figure 1. Pathogenesis and therapeutic options of CKD 
An underlying disease process sets in motion the cycle of nephron loss, which auto-augments by increasing 
podocyte shear stress and metabolic overload (leading to dysfunction of the proximal tubule). Various 
therapeutic options are available at different stages of the process, some of these are listed exemplary on the 
left. Modified after [6]. 
 
CKD can be caused by a range of different underlying diseases (Figure 1). Examples include polycystic 




(inflammatory/immunologic), bacterial pyelonephritis (infectious), fibromuscular dysplasia (vascular), 
lead nephropathy (toxic), obstructive nephrolithiasis (mechanical), or multiple myeloma (malignant). 
CKD can also result after a severe episode of acute kidney injury (AKI), causing irreversible kidney 
damage and leading to a permanent drop in GFR. Other factors predispose a person for CKD onset and 
accelerate CKD once it has manifested. These risk factors include obesity, low birth weight, aging, 
environmental and genetic factors, and pregnancy [4, 7, 8]. Obesity and pregnancy go along with an 
expansion of blood volume, leading to glomerular shear stress and causing glomerular hypertrophy 
and elevation of single-nephron GFR [4]. Low birth weight strongly correlates with fewer functioning 
nephrons at birth [9], leaving remaining nephrons to compensate by elevation of single-nephron GFR 
and hypertrophy, thus predisposing to CKD. 
Clinically, the presentation of CKD varies based on the underlying disease. Initially it is asymptomatic, 
which often delays diagnosis and treatment. When CKD has progressed, the patient may experience a 
range of symptoms including weakness from anemia. Once CKD approaches to kidney failure, body 
homeostasis is severely impaired by persisting kidney failure and a range of different signs and 
symptoms may appear. Uremic symptoms, which occur late in the disease process, include fatigue, 
nausea, vomiting, weakness, and anorexia. Signs of advanced kidney disease include arterial 
hypertension caused by fluid overload and maximum activation of the renin-angiotensin-aldosterone 
system (RAAS). Electrolyte abnormalities causing cardiac arrhythmia, cognitive impairments, or 
neuromuscular malfunction are frequently observed in kidney failure. Anemia due to a lack of 
erythropoietin production or mineral bone disorder due to an impaired vitamin D hormone 
metabolism are often earlier signs of advancing CKD and presentations of kidney endocrine 
malfunction. Cardiovascular disease (CVD)  is the main cause of mortality in patients with kidney failure 
and CKD [4]. 
Screening for CKD may be performed by measuring proteinuria and serum creatinine, which can be 
used to calculate the estimated GFR (eGFR). When screening yields a pathological finding, a cause must 
be determined. Here, the nephrologist will take a patient history and do a physical examination, 
additionally a large diagnostic repertoire is available including laboratory test, imaging, genetic testing, 
microscopy of the urinary sediment, and kidney biopsy to secure the underlying diagnosis. The 
determined underlying disease must then be treated to halt the progression of CKD. 
CKD treatment usually consists of specific medication of the underlying disease and general treatment 
approaches to slow CKD progression or prevent or treat CKD complications. For example, a patient 
with diabetic nephropathy will not only receive standard care for diabetes to control blood sugar like 
insulin and non-insulin anti-diabetic drugs but may also receive an SGLT2 inhibitor. This drug not only 




macula densa and decreases the glomerular filtration pressure, amplifying its nephroprotective effect 
in diabetic nephropathy [10, 11]. A recent study has shown that SGLT2 inhibition is also effective in 
CKD treatment of patients without diabetes [12]. General approaches to treating CKD that prevent 
further nephron loss by lowering single-nephron GFR and preventing CKD complications are applied 
regardless of the underlying kidney disease. RAAS blockade has been established as a cornerstone of 
CKD treatment. RAAS is responsible for the regulation of blood pressure and glomerular filtration 
pressure. In CKD, RAAS is overactive leading to arterial hypertension and glomerular hyperfiltration. 
This causes podocyte barotrauma and proteinuria with subsequent podocyte loss and leads to 
advancement of CKD by acceleration of nephron loss. Blockade of RAAS, either by inhibition of the 
angiotensin-converting enzyme (ACE) or by blockade of the angiotensin-II-receptor-subtype-I (AT1), 
leads to systemic vasorelaxation and causes normalization of arterial hypertension but also causes a 
reduction of glomerular filtration pressure and a decrease of single-nephron GFR by dilatating the 
efferent arteriole of the glomerulus. Another essential effect of RAAS inhibition seems to be the relief 
of the metabolic strain on the proximal tubule and a reduction of hyper-reabsorption (Figure 1) [6]. 
Therefore, RAAS inhibitors are used to break the vicious cycle described earlier and have been shown 
to have nephron-protective effects that can halt or slow the progression of CKD [13]. In Alport 
syndrome and diabetic nephropathy, treatment with RAAS blockade has been shown to be most 
effective when initiated as early as possible [14, 15]. Reducing protein and salt intake, controlling 
obesity, hypertension and dyslipidemia have also been shown to slow progression of CKD and diminish 
risk of kidney failure [16].  
Once kidney failure has set in, KRT must be started to further prolong the life of the patient. The most 
frequently used form of KRT is hemodialysis. The blood is accessed either by arteriovenous fistula, 
arteriovenous graft, or by placing a central venous dialysis catheter. The blood is then flown in the 
opposite direction of the dialysate, separated by a semipermeable membrane. Blood waste products 
diffuse across this membrane into the dialysate. Another option for KRT is peritoneal dialysis; here the 
dialysate is pumped straight into the peritoneal cavity by a catheter and blood waste products diffuse 
across the peritoneum into the dialysate. The dialysate is drained after an osmotic equilibrium has set 
in. The third option is a kidney transplantation. Dead and living kidney donations can be performed. 
Transplantation is the option with the best prognostic benefit for the patient, however, it is limited by 
organ availability [17].   
The European prevalence of CKD ranges from 3.31% in Norway to 17.3% in northeast Germany [18]. 
Within the Latin American population in the United State there is also great variability of CKD 
prevalence, ranging from 7.4% in South American women (11.2% in South American men) to 16.6 in 
Puerto Rican women (16.0% in “other” Latinos); the total Latino/Hispanic prevalence of CKD is 13.7 for 




million population (ppm) and lowest in the African countries of Senegal and Ghana [20]. The variance 
of CKD and kidney failure prevalence are likely caused by different environmental and genetic factors. 
In 2010, CKD was ranked 18th most frequent cause of death in the global burden of disease study, it is 
up from 27th place in 1990 [21]. Economically, CKD also poses a large burden. CKD and kidney failure 
are challenges for large scale economic systems; CKD and kidney failure cost a total of 4,659 million 
Euros in 2015 in Germany [22]. This is evidence that there is a vast unmet medical need in CKD and 
that research is needed to further understand CKD and its pathophysiology to develop improved 
treatment and preventative modalities.  
1.1.1 Aristolochic acid nephropathy 
One etiology of CKD relevant to this project is aristolochic acid nephropathy (AAN). Aristolochic acid 
(AA) is an herbal compound that can be found in Aristolochia fangchi or Aristolochia clematitis and has 
been responsible in the past for several regional outbreaks of nephropathy. AA was used in the past in 
Chinese herbal medicine to treat many different types of diseases like hepatitis, stroke, or pneumonia 
[23]. In the 1990s several Belgian women consumed ‘slimming’ medicinal tinctures containing AA and 
were found to have rapid progressive fibrosing interstitial nephritis [24], in some cases requiring kidney 
transplantation. Many patients with AA nephropathy later went on to develop urothelial malignancies 
[25], prompting the WHO to declare AA a class I human carcinogen [26].  
Long-term, small-dose exposure to AA was later declared the cause of the Balkan Endemic 
Nephropathy (BEN) that was first described in the 1920s. Contamination of wheat flour by Aristolochia 
clematitis, an herb that’s commonly found in Balkan wheat fields was described by Ivic in 1969 [27] as 
a possible cause for continuous environmental exposure to AA. In endemic areas of eastern Europe, 
BEN is responsible for 70% of kidney failure [28]. Although prevalence BEN or AAN peaks in regions 
where members of the Aristolochia plant are at home, evidence suggests that AAN is a global problem 
and presents a great unmet medical need [28, 29].  
AA is a mix of two structurally similar nitrophenanthrene carboxylic acids: 8-methoxy-6-nitro-
phenanthro-(3,4-d)-1,3-dioxolo-5-carboxylic acid (AAI) and 6-nitro-phenanthro-(3,4-d)-1,3-dioxolo-5-
carboxylic acid (AAII) [30]. AAI and AAII undergo redox reactions and their reduced forms form covalent 
adducts with DNA. This blocks mRNA transcription and DNA replication, leading to cell cycle arrest and 
p-53 dependent cell death [31]. This mechanism likely explains the observed tubular necrosis in AAN. 
It is not known why the kidney is primarily affected. Similarly, the mutagenic potential explains the 
compounds propensity to cause urothelial carcinoma.  
The clinical presentation of AAN includes kidney insufficiency, anemia, erythrocytes and leukocytes in 




histological findings are massive interstitial fibrosis and associated tubular atrophy, tubular necrosis, 
hyperplasia of arteriolar walls, and few interstitial inflammatory cells [23]. Around 40% of patients also 
present with urothelial carcinoma in situ [32]. Phytochemical analysis can confirm intake of AA and 
DNA adduct analysis can be used to confirm the presence of AA DNA adducts in biopsied kidney or 
urothelial tissue [23]. 
Treatment options of AAN are greatly limited. Individual reports have observed altered disease courses 
under steroid therapy [33, 34]. Beyond steroids, general management of CKD and kidney failure, 
including KRT, is indicated. Patients should be regularly screened for urothelial malignancies.  
AA is used in an experimental setting to induce CKD in mice [35]. It models the effects of AAN in human 
and is a simple and fast way to induce kidney fibrosis in mice.  
1.2 Uric Acid Metabolism 
Uric acid (UA) is the end-product of the purine metabolism. It is a weak diprotic organic acid with a 
pKa1 ≈ 5.4 and pKa2 ≈ 10.3. At the human physiological blood pH of 7.4, 1% is found as the electrically 
neutral UA and 99% of it is deprotonated once and present as the monovalent urate anion [36]. 
Biochemical literature uses the two terms urate and uric acid interchangeably for all protonation 
states. UA as bivalent anion is almost nonexistent in humans, due to its very basic pKa2. UA has a 
solubility limit of about 7 mg/dl under physiological conditions (pH of 7.4, 37 °C). For this reason, blood 
UA concentrations above 7 mg/dl are considered hyperuricemic (varying slightly depending on the 
measuring laboratory and between men and women). The electrically neutral, undeprotonated UA has 
a much lower solubility limit, predisposing for crystal formation in acidic environments like urine.   
Higher primates, including humans, have lost function of the hepatic uricase, an enzyme used by most 
other animals including rodents to degrade UA into the more water-soluble allantoin. This leads to 
higher serum UA levels in higher primates and humans compared to lower mammals. In 
normouricemic humans, the concentration of serum UA is close to its solubility limit, predisposing 
humans to precipitation of UA crystals in the tissue, and therefore to all UA crystal-related pathologies.  
1.2.1 Synthesis and Degradation of Purines 
De novo purine synthesis begins with ribose-5-phospahte, which is created in the pentose phosphate 
pathway, a sugar metabolism pathway. The phosphoribosyl pyrophosphate synthetase converts 
ribose-5-phosphate to phosphoribosyl pyrophosphate (PRPP) [37]. PRPP is enzymatically converted, 
over various intermediary products, into inosine monophosphate (IMP), which in turn is converted to 
guanosine monophosphate (GMP) or adenosine monophosphate (AMP), that make up the building 




pyrimidine bases thymine, cytosine, and, uracil. In the first step of AMP degradation, AMP is converted 
into IMP and  then into hypoxanthine by the purine nucleoside phosphorylase [38]. Hypoxanthine is 
oxidized to xanthine by the xanthine oxidase. The metabolic pathway of GMP degradation merges into 
xanthine over guanosine and guanin. Xanthine is further oxidized to UA by the xanthine oxidase, ending 
the degradation pathway of purines in humans because of the missing urate oxidase (uricase). Figure 
2 gives a detailed overview of the degradation of purines to UA. There is a salvage pathway for guanine 
and hypoxanthine, which can be recycled into GMP and IMP by the hypoxanthine–guanine 
phosphoribosyltransferase (HGPRT). A mutation in the gene encoding for the HGPRT causes Lesch–
Nyhan syndrome, which is characterized by hyperuricemia with gout, reduced intellect, and self-
mutilating behavior [39]. The adenine phosphoribosyltransferase (APRT) catalyzes the salvage 
pathway for adenine, recycling it to AMP. A deficiency of APRT leads to accumulation of 2,8-
Dihydroxyadenine, a byproduct of the adenine metabolism, causing 2,8-Dihydroxyadenine 
nephrolithiasis and crystalline nephropathy [40]. 
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Figure 2. Uric acid synthesis  
The degradation pathway of purines begins with the purine monophosphates. AMP is converted to IMP via the 
AMP deaminase. All purine monophosphates are dephosphorylated by the 5’-nuclotidase. The resulting 
nucleosides are further degraded by the purine nucleoside phosphorylase. This enzyme degrades the nucleosides 
to into their corresponding bases. The bases are enzymatically converted to xanthine, which is oxidized by the 





1.2.2 Elimination of UA 
Humans and other mammals rely on urea, not UA for the excretion of nitrogen. Birds and snakes, 
however, with a fractional excretion of UA greater than 100%, use UA as primary vehicle for the 
elimination of nitrogen, demonstrating vast differences in the kidney handling of UA between animals 
[36]. UA is eliminated by the kidney through the urine or by the gut. The gut eliminates about 25 to 
33% of the total UA [42]. Here, UA is secreted into the intestinal lumen, where it is degraded to 
allantoin by colonic bacteria. 
1.2.3 Kidney Excretion of UA 
The kidney is responsible for the elimination of the rest of the UA (75 to 66%) in humans and the kidney 
handling of UA is decidedly more complex. The fractional excretion of UA (FEUA) is approximately 
equal to the ratio of UA clearance (CUA) and to the ratio of creatinine clearance (CCr), which are 
calculated using plasma and urine UA (PUA, UUA) and creatinine concentrations (PCr, UCr), therefore: 
FEUA = CUA/CCr × 100% = [(UUA × urine sample volume)/ PUA]/[(UCr × urine sample volume)/PCr] × 100% 
= (UUA × PCr)/(PUA × UCr) × 100%. This formula assumes that creatinine has a fractional excretion of 100% 
and is therefore neither absorbed nor filtered by the human kidney tubule. The FEUA is around 10% in 
adults, meaning that 10% of the filtered UA is excreted by the urine and 90% is reabsorbed into the 
bloodstream [43]. Infants have the highest FEUA at around 27%, declining to a mean of FEUA in 
childhood around 8% despite rising serum urate levels and therefore increased UA glomerular filtration 
[44-46].  
UA has a molecular weight of 163.1 Dalton, therefore passing the glomerular filter unhindered. It is 
evident that if kidney FEUA is below 100%, there needs to be a tubular reabsorption of UA. In 1959, A. 
Gutman et. al. found evidence of tubular secretion of urate [47], therefore setting up a three-
component system for kidney handling of UA: filtration, reabsorption, and secretion [48]. Evidence for 
postsecretory reabsorption was found 14 years later in a study of humans, where subjects received 
treatment with probenecid or sulfinpyrazone at a low dose compared to a high dose (both uricosuric 
agents that block kidney urate reabsorption [49, 50]), leading to an apparent increase of UA secretion 
as measured by a greater decrease of uricosuria after administration of pyrazinamide or low-dose 
aspirin (both thought to inhibit tubular secretion of UA [51, 52]). The authors concluded that this 
finding is more compatible with a partial reabsorption distal to the secretory site of UA in the tubule 
[53]. This led to the formation of the “classical” model of kidney UA excretion: 1st glomerular filtration 
of urate; 2nd presecretory reabsorption in S1 segment of the proximal convoluted tubule, where about 
99% of the filtered UA is reabsorbed; 3rd secretion in the S2 segment 50% of the reabsorbed UA is 
secreted back into the tubular lumen; and 4th postsecretory reabsorption in the S3 segment, where 




Figure 3 gives an overview of nephron anatomy for orientation. Newer research has amended the strict 
order and segment-based placement of reabsorption and secretion that is described in the classical 
model and has shown that reabsorption and secretion via urate transporters can take place in the 
same part of the proximal kidney tubule [55]. The cause of hyperuricemia in patients taking the 
tuberculostatic medication pyrazinamide has also been revised by more recent research suggesting 
that it is at least in part explained by stimulation of urate reabsorption as opposed to only the inhibition 
of urate secretion [56, 57], therefore amending previous research that was crucial to the establishment 
of the classical model that assumed an effect of pyrazinamide only on tubular urate secretion. 
 
Figure 3. Nephron anatomy 
A schematic overview of nephron anatomy is shown. The glomerulus is responsible for the filtration of blood into 
the Bowman’s capsule, forming the “glomerular filtrate”. This liquid is conducted into the proximal convoluted 
tubule, where the S1 and part of the S2 segment sits. The S2 segment extends into the straight proximal tubule 
(thick descending limb of the loop of Henle), leading into the S3 segment. The filtrate then passes into the thin 
descending limb and thin ascending limb of the loop Henle, the thick ascending limb, the distal convoluted tubule, 





1.2.4 Kidney Urate Transporters 
URAT1 
URAT1, discovered in 2002, was the first kidney urate channel to be identified [57]. It is encoded by 
the SLC22A12 (solute carrier family 22, member 12) gene and part of the organic anion transporter 
(OAT) family. It is expressed in humans at the brush border (luminal) of human kidney tubular 
epithelium and responsible for UA reabsorption. Genome wide association analyses identified an 
association between serum UA levels and sequence variation of the SLC22A12 gene [59], providing 
further evidence for the role of URAT1 in UA metabolism. First functional studies were performed by 
cloning it into Xenopus oocytes; here, it was shown to take up UA in exchange for Cl- or organic anions 
(antiuricosuric agents like pyrazinamide, lactate, aspirin serve as substrates for URAT1, increasing UA 
reabsorption) with a Michaelis constant (Km) of 371 ± 28mM it is a target of benzbromarone and 
probenecid, the most commonly used uricosuric gout medication. Evidence for its importance in 
tubular reabsorption of urate was provided by the identification of congenital SLC22A12 loss of 
function mutation as the cause of renal hypouricemia in Japanese patients [57, 60-62]. These patients 
have an FEUA of 30-90% and suffer from nephrolithiasis and exercise-induced acute kidney failure [63]. 
Although their FEUA is much higher than that of healthy individuals, there is still net rest-reabsorption 
of UA even in patients with homozygous loss of function URAT1, meaning that URAT1 cannot be the 
only apical kidney transporter responsible for UA reabsorption.  
GLUT9 
The SLC2A9 gene, coding for GLUT9, was identified as having a cDNA sequence corresponding to a 
member of the human glucose transporter (GLUT) family. It was first cloned in 2000 and identified to 
have 12 transmembrane domains  [64], similar to other transporters of this family. It is present in two 
splice variants that have distinct expression patterns: GLUT9 (aka GLUT9a), which is expressed in 
kidney, liver, placenta, and leukocytes, whereas GLUT9ΔN (aka GLUT9b) is only expressed in kidney 
and placenta [65]. In polarized Madin-Darby canine kidney cells GLUT9a was found in the basolateral 
membrane, whereas GLUT9b in the apical membrane. GLUT9 has a low affinity for deoxyglucose and 
it was not until 2007 that a role for UA handling was suggested for GLUT9 by genome wide association 
studies (GWAS) of two cohorts in Sardinia and Chianti [66]. Subsequent GWAS confirmed this 
association in other cohorts [67-69] and its heterologous expression in Xenopus laevis oocytes showed 
a strong UA transport activity of GLUT9. GLUT9 is a voltage dependent uniporter of UA and does not 
depend on the Na+ transmembrane gradient [70]. It was shown that homozygous loss of function 




and a phenotype of UA nephrolithiasis and exercise-induced acute kidney failure [71-73]; it has also 
been described to cause posterior reversible encephalopathy syndrome [74]. Heterozygous loss of 
function mutation leads to a less pronounced phenotype of hyperuricosuria and renal hypouricemia 
[75-77]. Together, these findings suggest that GLUT9a is possibly the only tubular basolateral 
transporter for UA, while the apical GLUT9b has been hypothesized to play a role in tubular UA 















Figure 4. Transporters involved in tubular reabsorption and secretion of UA. 
Pictured schematically are UA transporters of epithelial cells in the proximal tubule with the arrows indicating 
the direction of UA movement. UA reabsorption is performed on the apical (luminal) tubular membrane GLUT9b, 
URAT1, and, to a lesser extent, OAT4. GLUT9a is most likely the only reabsorption transporter for UA on the 
basolateral side of the tubular cell. A range of UA transporters have been shown or are hypothesized to play a 





Other kidney UA Transporters 
A range of other UA transporters have been descried in the literature, however, the level of evidence 
for their roles in kidney handling of UA remains less than for GLUT9 and URAT1.  
Other members of the OAT family have been shown to transport UA and are expressed in kidney 
tubular epithelium. OAT4 is an apical transporter of the proximal tubule and has been associated with 
hyperuricemia and gout in different GWAS [78-81]. It is sequentially similar to URAT1 and transports 
UA at a lower affinity. A study found that a variant of OAT4 leads to underexcretion of UA and 
predisposes patients to develop gout [82], which highlights its role in kidney UA handling. OAT10 was 
shown to transport UA at a very low affinity [83] but GWAS have not been able to show an association 
with gout or hyperuricemia for this transporter [59]. 
A range of different transporters have been postulated to potentially play a role in tubular secretion 
of UA. Multidrug resistance protein (MRP) 4, Apical ATP-binding cassette transporter G2 (ABCG2), 
human sodium phosphate transporter 4 (hNPT4/SLC17A3), NPT1 (SLC17A1), and Type 1 sodium-
dependent phosphate transporter (SLC17A1 Protein) have all been shown to transport UA in vitro and 
are present on the apical side of human tubular cells [84-87]. ABCG2, NPT1, and NPT4 have been 
associated with hyperuricemia and gout in GWAS [59, 67, 80, 81]. OAT1, OAT2, and OAT3 are expressed 
basolaterally and have been hypothesized to play a role in tubular secretion by transporting urate from 
the kidney interstitium into the tubular epithelium [88]. Evidence for the role of these secretory 
transporters in vivo remains weak and pending further investigation. Figure 4 shows the function of 
each UA transporter in a tubular cell. 
1.3 Gout  
Gout is an inflammatory form of arthritis caused by the deposition of monosodium urate (MSU) crystals 
within joints and soft tissues. The deposition of MSU crystals is caused by pathologically elevated 
serum UA levels, called hyperuricemia.  
The precipitation of MSU crystals triggering acute inflammation of the affected joint is called acute 
articular gout. Most commonly affected is the base joint of the big toe, a manifestation of gout called 
podagra. Advanced gout usually presents many years after initial onset of symptoms. Here, persisting 
UA crystals cause chronic inflammation, leading to the formation of granulomas around the crystal. 
This granuloma, in the case of gout, is called tophus. Within the tophus, both pro- and anti-
inflammatory cytokines are excreted, leading to a state of low-level chronic inflammation [89]. 
Histologically, larger crystal masses are surrounded by layers of epithelioid mononuclear cells and 
foreign-body giant cells (fused macrophages, another hallmark of tophi). The tophus is encapsulated 




surrounding tissue from crystals and vice versa. Articular tophi can lead to bone destruction, loss of 
joint function, and joint disfigurement [90]. The morphology of articular gouty tophi is identical to the 
kidney UA tophi (see section 1.5.2). 
The rate of gout is higher among men (3-6%) than among women (1-2%) [91]. The total incidence in 
the 2000s is 2-68 per 1000 person/year. Gout is more likely with higher age [91]. Significant comorbid 
disorders include hypertension (74%), CKD stage II or higher (71%), obesity (53%), diabetes (26%), and 
a history of myocardial infarction (14%) and stroke (10%) [92]. Risk of death in patients with gout is 
also increased, usually due to cardiovascular disease [93]. Whether or not the increased prevalence of 
these comorbid conditions is causally attributed to hyperuricemia or gout has been difficult to prove 
due to many potential confounding factors. However, some evidence suggests that hyperuricemia and 
gout directly contribute to worse outcomes in CKD and cardiovascular disease [94-96].  
1.4 Hyperuricemia 
There are a few useful physiological properties of UA making it likely that humans have garnered an 
evolutionary benefit by loss of uricase function, resulting in higher blood urate levels. One such 
property is its antioxidant function. It was shown that soluble UA (sUA) can reduce the oxo heme 
oxidant formed in the oxidation of hemoglobin with peroxide and can protect erythrocytes from lysis 
due to peroxidative damage. UA is also a powerful scavenger of hydroxy, singlet oxygen, and peroxyl 
radicals [97]. UA is therefore hypothesized to cause lengthening of lifespan due to protective 
mechanisms against oxygen radicals, decreasing incidence of cancer [97]. Early humanoids lost the 
function of the L-gulonolactone oxidase, the enzyme responsible for the production of ascorbic acid 
(Vitamin C), thus increasing selection pressure to find an alternative antioxidant and setting the stage 
for the loss of uricase function. In vivo data has shown significant reduction of ischemic changes in a 
rat model of cerebral artery occlusion when animals were treated with serum UA compared to placebo 
[98]. A mouse model of multiple sclerosis (MS) showed a strong, dose-dependent, therapeutic effect 
of UA. The same study showed a significantly lower level of serum UA in patients with MS compared 
to controls and that patients with both gout and MS were significantly less frequent in a large cohort 
of MS and gout than predicted mathematically  [99]. The authors of both studies ascribed their findings 
to the antioxidant properties of sUA.  
Other research, contrarily, has found that sUA, under certain conditions, also has radical oxidative 
properties [100-102]. When oxidized, sUA does not always turn into its neutral redox partner allantoin 
but also into radicals like the aminocarbonyl radical, which can amplify oxidation of LDL liposomes by 
peroxynitrate [103], possibly aiding in the pathogenesis of arteriosclerosis and adding to the oxidative 




dysfunction, which can stimulate NADPH oxidases, leading to endothelial dysfunction and possibly 
aiding in the pathogenesis of hypertension and vascular disease [104]. Hyperuricemia is 
epidemiological closely correlated to diseases with a high oxidative burden such as metabolic 
syndrome, arteriosclerosis, obesity, and hypertension. A randomized placebo-controlled clinical trial 
found that serum UA levels independently predict cardiovascular events in patients with isolated 
systolic hypertension [105]. This paradox could be explained as a counterregulatory measure of the 
body, increasing serum UA levels to deal with a higher oxidative stress. In contrast, hyperuricemia 
could also be a causative agent in the pathogenesis of these diseases. Mouse models of hyperuricemia 
have also produced conflicting data. A study using an inducible, liver-specific Glut9-KO murine model 
of hyperuricemia found no evidence of hypertension after 6 months of an average serum UA of 300 
µmol/l [106]. A more recent study using urate oxidase (Uox) knockout mice found development of 
hypertension and aberrant fat metabolism in female mice and decreased glucose tolerance in male 
mice [107]. It should be noted, however, that serum UA in the second study was much higher (above 
460 µmol/l, a level that is considered hyperuricemic even for humans), that only 40% of the mice 
survived up to 62 weeks, and that the development of hypertension in the Uox-KO mice could also be 
explained by a higher level of kidney damage secondary to hyperuricemia. More research is needed to 
clarify, which properties (antioxidant or oxidant) of sUA overweighs and therefore whether sUA plays 
a protective or a detrimental role in human metabolism. 
Another theory seeking to explain an evolutionary advantage behind the loss of uricase function 
considers its dependent anti-natriuretic and therefore blood pressure elevating effects, that was 
observed in a hyperuricemic rat model [108]. Loss of uricase function happened at a time of low 
sodium availability for humans, and sUA is postulated to maintain blood pressure levels to compensate 
for dietary sodium deficiencies [108, 109]. Evidence that asymptomatic hyperuricemia leads to 
increased blood pressure was also provided in an interventional study of hyperuricemic adolescents, 
where a decrease in blood pressure was observed after treatment with allopurinol was initiated [110]. 
However, this study is limited by a range of factors including a low number of study subjects (n=30) 
and further research is needed to establish this causality. If true, however, this second theory explains 
an evolutionary benefit of sUA in times of low dietary sodium availability in maintaining blood pressure 
and at the same time its propensity to cause morbidity due to hypertension in times of dietary sodium 
abundance, as is the case today. 
1.4.1  Hyperuricemia in gout 
In lower mammals, with retained uricase function, serum UA concentrations never approach the 
solubility limit. In humans, however, the missing uricase genetically predisposes to hyperuricemia and 




bradytroph tissue, with a lower pH and temperature, all of which further increases the likelihood of 
UA precipitation. The crystals elicit an acute inflammation by triggering NLRP3 inflammasome 
activation and subsequent secretion of interleukin (IL)-1β [111], leading to leucocyte recruitment, 
neutrophil activation, and painful inflammation. This is the pathophysiology of acute gouty arthritis. 
Inflammation is finally resolved by aggregation of neutrophil extracellular traps (NETs), phagocytosis 
of apoptotic neutrophils by macrophages and release of anti-inflammatory cytokines [112].  
The causal relation between hyperuricemia and gout is unquestioned in the literature. In 1859, Alfred 
Garrod showed in his now legendary publication “The nature and treatment of gout and rheumatic 
gout” that “the deposited urate of soda may be looked upon as the cause, and not the effect, of the 
gouty inflammation” [113]. Garrod also developed the first semi-quantitative test for UA in the blood 
and urine [114]. Much later, in 1963, allopurinol was developed and it was shown that xanthine oxidase 
inhibition lowers serum UA and effectively prevents gout [115]. 
Management of gout is based on two different principles: treatment of the acute inflammatory flare 
and urate-lowering, prophylactic, therapy. In the acute flare, non-steroidal anti-inflammatory drugs 
(NSAIDs), colchicine, and glucocorticoids are used to aid resolution of inflammation. If the patient has 
more than one flare per year, tophi, CKD stage 2 or higher, or kidney stones, urate-lowering therapy is 
indicated [116]. Medication of choice are usually xanthine oxidase inhibitors like allopurinol or 
febuxostat, but uricosuric agents (via blockade of URAT1 in the kidney) are alternatives. It is important 
to mention that a rapid initiation of urate-lowering therapy has been described to induce acute flares 
[117] and anti-inflammatory therapy is recommended as prophylaxis during the first six months of 
uricostatic therapy.  
1.4.2 Hyperuricemia in CKD 
Hyperuricemia and CKD are epidemiologically closely related, and many studies aim to elucidate, which 
of the two causes the other. A lot of these studies aim to devise the role of asymptomatic 
hyperuricemia in CKD using regression models. 
As CKD progresses, there is less kidney elimination of UA, causing serum UA levels to rise. By the time 
kidney failure is reached and dialysis is initiated, nearly all patients are hyperuricemic [118]. More 
complex is the question whether hyperuricemia in turn causes or leads to the progression of CKD. 
Studies of patients with preexisting CKD have found that hyperuricemia does not independently 
predict its progression [119, 120]. This finding can possibly be explained by the fact that CKD leads to 
water and sodium retention, therefore causing vascular disease and CKD progression independently 
and to a greater degree than hyperuricemia alone [121]. Support for this hypothesis comes from 




independently predict development of CKD and kidney failure [122-124]. Hyperuricemia has also been 
shown to independently predict progression of CKD in patients with diabetic nephropathy and Ig-A 
nephropathy [125, 126]. It can be said that hyperuricemia consistently predicts the development but 
not the progression of CKD. As patients reach kidney failure, there is a J-shaped mortality in patients, 
as high and low UA levels are associated with a bad outcome [118, 127].   
Hyperuricemia is associated with obesity, metabolic syndrome, and insulin resistance [128]. 
Hypertension has also been shown to cause hyperuricemia by producing kidney vascular constriction, 
leading to kidney nitrogen retention [129]. This could be an explanation for the observation that 
hyperuricemia often presents before CKD onset. Others have argued that hyperuricemia can precede 
these conditions, [121] leading to the same chicken and egg dilemma so frequently encountered when 
studying hyperuricemia. A high fructose diet and the excessive consumption of meat and beer are also 
associated with hyperuricemia [130]. Studies have shown that feeding of a high fructose diet can 
induce features of metabolic syndrome in rats like hyperinsulinemia, hypertension, hyperlipidemia, 
and hyperuricemia and that administration of allopurinol, febuxostat, or benzbromarone 
prophylactically prevents hyperinsulinemia [131, 132].  
Intoxication of lead blocks kidney excretion of UA, leading to hyperuricemia [133]. Lead exposure, 
especially long term, low level lead intoxication strongly correlates with CKD [134]. Animal models with 
preexisting CKD have shown augmentation of kidney disease upon lead intoxication. After 
administration of allopurinol, a reduction of hypertension was observed in these animals [135]. 
Another technique to approach the chicken and egg problem concerning hyperuricemia and CKD is to 
use interventional studies with urate-lowering medication. A study of 54 hyperuricemic patients with 
CKD found that allopurinol preserved kidney function over the course of 12 months compared to 
controls, where kidney function deteriorated [136]. Likewise, a study of 113 patients with a GFR below 
60 ml/min showed a slow of progression of CKD when treated with 100 mg of allopurinol daily [137]. 
Another study of patients with diabetic nephropathy secondary to Type II Diabetes showed a reduction 
of proteinuria after 4 months of allopurinol therapy [138]. A meta-analysis of 11 studies with a total of 
753 patients showed that UA lowering therapy leads to a decrease in serum creatinine and an increase 
of GFR [139]. Another study of 7629 patients showed that hyperuricemia correlated with a falling GFR 
and an increase in cardiovascular events [140]. 
Much of the above presented research implies a harmful role of hyperuricemia in cardiovascular and 
kidney disease. Citing many of these studies, a review by Johnson et. al plead for more clinical trials 
studying the effect of uricostatic therapy on the progression of CKD or CVD [121].  However, whether 




guidelines do not recommend uricostatic therapy of asymptomatic hyperuricemia, even in patients 
with CKD.  
1.5 Uric acid crystal nephropathy  
Two different types of UA crystal nephropathy have been defined in the literature: acute and chronic 
UA crystal nephropathy. Acute UA crystal nephropathy is caused by acute massive hyperuricemia, as 
seen in patients with tumor lysis or crush syndrome. Here, the massive decay of cells causes the release 
of high quantities of UA into the bloodstream. The UA is filtered in the glomerulus and concentrated 
by the tubule after fluid reabsorption, causing UA to exceed its solubility and precipitates out, leading 
to tubular occlusion and acute kidney injury. Chronic UA crystal nephropathy is a pathological diagnosis 
that is usually made incidentally on kidney biopsy. Its hallmarks on light microscopy are medullary UA 
tophi. These tophi consist of central needle shaped clefts that are left behind by the crystal after it is 
dissolved out during tissue fixation and surrounding mononuclear inflammatory infiltrate embedded 
in fibrosis [141].  
1.5.1 Acute uric acid crystal nephropathy (in tumor lysis or crush syndrome) 
One of the most common medical emergencies in tumor patients, especially in patients with 
hematologic malignancies, is the tumor lysis syndrome. This occurs when large amounts of malignant 
cells undergo lysis, often due to cytostatic therapy, and intracellular content is released into the 
bloodstream. The Cairo and Bishop system is used to classify the tumor lysis syndrome based on 
metabolic laboratory findings and clinical findings [142]. Two or more of the following laboratory 
abnormalities are required to complete the criteria for laboratory tumor lysis syndrome: hyperkalemia, 
hyperphosphatemia, hyperuricemia, and hypocalcemia. Clinical tumor lysis syndrome is defined as 
laboratory tumor lysis syndrome plus seizures, increased serum creatinine, cardiac arrythmia, or death 
[142]. Kidney failure in tumor lysis syndrome is caused partly by acute UA crystal nephropathy. Here, 
purines from the nucleus of the lysed tumor cells are metabolized to hypoxanthine and then oxidized 
to xanthine, which is in turn oxidized to UA. These oxidation steps are catalyzed by the Xanthine 
oxidase. The UA is filtered freely in the glomeruli and precipitates out in the tubules, causing tubular 
occlusion and AKI.  
The rapid progression of acute UA crystal nephropathy makes it a medical emergency requiring 
immediate treatment. Besides volume and shock therapy, a few pharmaceutical options are available 
for the treatment and prophylaxis of tumor lysis syndrome. Urine alkalization may be used to attempt 
to elevate the intratubular solubility limit of UA. Rasburicase is a recombinant enzyme that, similarly 
to the uricase in other mammals, catalyzes the oxidation of UA to the better soluble allantoin, 




UA in the blood, making i.v. rasburicase the treatment of choice for manifest tumor lysis syndrome 
[144]. Xanthine oxidase inhibition, with allopurinol or febuxostat, is another approach to 
pharmaceutically prevent acute UA crystal nephropathy in patients that are at risk for tumor lysis 
syndrome. This medication blocks the production of UA from purines, making it a useful tool in the 
prevention of acute UA crystal nephropathy; however, it has no effect on existing blood UA burden, 
therefore making it inferior to rasburicase in the treatment of manifest tumor lysis syndrome [145].  
1.5.2 Chronic gouty nephropathy 
The pathognomonic feature of chronic gouty or chronic UA crystal nephropathy are UA tophi in the 
medulla of the kidney. A gouty tophus consists of three layers: On the inside there is a needle-shaped 
UA crystals, these crystals are usually dissolved by the fixation process, leaving a needle shaped cleft. 
The UA crystal tophus is surrounded by several epithelioid layers of mononuclear cells, also 
characteristic of tophaceous granulomas are multi-nucleated giant cells, which are formed by the 
fusion of macrophages. This complex of crystals  and surrounding inflammatory infiltrates is embedded 
in medullary fibrosis, making up the outer layer of the tophus [146]. 
First observations of a link between gout and kidney disease date back to the 1500s. In the late 1800s, 
white streaks of deposit were first observed by Sir Alfred Garrod in the pyramids of a gouty patient’s 
kidney and identified as “soda of urate” [147]. Upon further analysis, Garrod described these deposits 
to lie within fibrotic tissue between the kidney tubuli, making his, the first account of kidney gouty 
tophi in literature. In 1952, Modern and Meister described a new clinical entity, which they called “the 
kidney of gout” [148]. The clinical features of this new entity, which they termed "specific renal lesion 
of gout" were characterized in three patients and consisted of kidney insufficiency, fixed urinary 
specific gravity, azotemia, normal blood pressure, and the absence of proteinuria or formed elements 
in the urinary sediment [148]. An autopsy was performed in one of these patients, and the authors 
described kidney tophi, tubular atrophy, and interstitial fibrosis.  
This newly described kidney manifestation of gout was characterized further in 1950 by Talbott and 
Terplan. In their study, they reviewed 279 autopsy or pathology reports of patients with articular gout 
[149]. They described most frequently pyelonephritic scars; intrarenal tophi, which were often 
surrounded by or obscured by stellate sears; arterial sclerosis; and interstitial fibrosis. Talbott and 
Terplan found that patients with severe tophaceous articular gout had the most abnormal kidney 
findings. However, they also noted several individual discrepancies between the severity of gout and 
the extend of kidney damage [149]. 
In 1968, Barlow and Beilin studied the kidney biopsies of 25 patients with primary gout. In almost every 




[150]. They also stated that the most specific renal lesion in this collective of gouty patients was the 
presence of crystalline deposits, which they reported to have found in 90% of gouty kidneys in the 
form of micro calculi in the collecting ducts and needle shaped medullary deposits often surrounded 
by inflammatory cells [150]. In a series of non-selected 1733 autopsies, a study from 1981 found 
medullary UA deposits in 8% [151]. The authors found a statistically significant association between 
the presence of gouty tophi and a clinical history of articular gout and “renal disease of apparently 
primary, but not gouty, origin” [151]. However, although there was a statistical correlation, 86% of 
patients with kidney tophi did not have clinical gout. This study and a similar study showing a large 
discrepancy between medullary UA tophi and clinical gout lead to the conclusion that the presence of 
UA tophi cannot be used as a diagnostic for gout.  
There is a tight association between hyperuricemia and CKD, and it is known that kidney impairment 
causes elevated blood UA levels by retention of nitrogen compounds [121]. It has, however, not been 
established whether chronic mild hyperuricemia in turn causes kidney impairment, and if so, by what 
mechanism. Many authors have postulated that medullary gouty tophi, which build up due to 
persistent asymptomatic hyperuricemia with or without articular gout, are one mechanism that could 
explain this observed relationship [54, 148, 152]. Two large reviews, however, have argued the 
contrary, supporting the claim that medullary gouty tophi are likely a benign byproduct of metabolism 
and have no pathological value [147, 153]. Here the authors argue that there is not enough evidence 
to support the claim that medullary gouty tophi actively cause kidney impairment. On the contrary, 
the authors declare that kidney damage observed in patients with hyperuricemia and gout can be 
attributed entirely to confounding factors like hypertension, vascular disease, genetic disorders, or 
lead intoxication. In the recent years, research on medullary gouty tophi has stagnated, and especially 
evidence in animal models on chronic gouty nephropathy remains scarce. The exact pathophysiology 
remains unknown. There are authors that postulate that the crystals within the tophi come from the 
inside of a ruptured tubule [152, 153] and others that propose they primarily of extra-tubular origin 
[147]. The elucidation of the pathogenesis of medullary tophi would aid greatly in determining their 
clinical relevance. Presently there are no treatment recommendation for this finding. 
1.6 Animal models of hyperuricemia and uric acid crystal nephropathy  
Hyperuricemia and its complications, including gout, are difficult to study in murine models. The main 
reason behind this being the difference in UA physiology and metabolism of mice or rats compared to 
humans. Uricase function remains conserved in rodents, leading to a much lower serum UA than in 
humans. The average serum UA concentration C57BL/6 mice is 1.44 mg/dl [154], whereas in humans 
the average serum UA is 6-8 mg/dl. Loss of uricase function has led humans to evolve effective 




Although many of the same UA transporters have been described for human and rodent kidneys, they 
differ in their affinity for UA and their localization within the nephron.  
Human URAT1, with a Km of 370 µM, has a higher affinity for UA than its murine ortholog, called mouse 
renal-specific transporter (RST) with a Km for UA of 1200 µM [155, 156]. RST knockout mice have only 
a very mild increase of FEUA (increase from 3% in healthy to 5% in KO-mice) [157] compared to an 
extreme increase of FEUA, which rises from 10% in healthy humans to 30-90% in humans with 
SLC22A12 loss of function mutations [63]. Murine Glut9 differs from human GLUT9 in its localization 
within the kidney. Human GLUT9 is found only in the proximal tubule and on the basolateral 
membrane; whereas mGlut9 is also found in the distal tubule and the apical membrane [158], further 
highlighting differences between mouse and human kidney urate handling at a molecular level.  
Murine models of hyperuricemia can be created by knockout or inhibition of the hepatic urate oxidase. 
Hyperuricemia can also be induced in mice by knockout of Glut9 in the liver, leading to loss of access 
of UA to the hepatic uricase and therefore indirectly inactivating it. Most mouse models of 
hyperuricemia lead to an acute UA crystal nephropathy with tubular deposition of crystals and kidney 
injury, similar to patients with tumor lysis or crush syndrome. This demonstrates the importance of 
Uox in murine UA metabolism and the inability of proper UA handling by the murine kidney, when the 
Uox function has been impaired. Hyperuricemia in rodents cannot be achieved without in some way 
impeding or restricting Uox function; even HPRT-deficient mice, which are used as an animal model of 
Lesch-Nyhan syndrome (an x-chromosomal dominant disorder that leads to cognitive impairment, self-
mutilation and hyperuricemia in humans), are not hyperuricemic because the function of the urate 
oxidase remains intact [159, 160]. 
1.6.1 Oxonic-acid induced hyperuricemia 
The first rodent models of hyperuricemia were created by administration of oxonic acid and UA p.o. 
into rats [161]. Oxonic acid inhibits the function of the hepatic urate oxidase, leading to hyperuricemia 
(above 3 mg/dl), which is further augmented by the additional injection of UA. These rats developed 
moderate hyperuricemia and severe hyperuricosuria. Acute tubular injury was observed after one 
month followed by mild chronic interstitial nephritis at 36 to 52 weeks [161]. Oxonic acid has since 
been frequently used as a non-transgenic animal model of hyperuricemia. It is an easy model to use, 
and can be applied in rodents as well as other animals, like rabbits, and used with or without 
augmentation of UA or Adenine [162-165]. In 1975, Bluestone et al. were able to produce gouty tophi 
in vivo using an oxonic acid-induced hyperuricemia rat model [161]. However, this was an inconsistent 




1.6.2 Uricase knockout 
The liver enzyme uricase can also be knocked out, leading to hyperuricemia from birth. Compared to 
the oxonic acid model, in this model, hyperuricemia is much more profound (above 7 mg/dl) as these 
mice have no functioning uricase [107]. A systemic uricase knockout causes severe urate nephropathy 
leading to death in more than half of all born mice before the age of 4 weeks from urate nephropathy 
unless maintained on allopurinol [107, 166]. This, once again, indicates the importance of uricase 
function in murine UA homeostasis and shows that rodent kidneys are ill equipped to handle a high 
UA load. Due to the severity of illness caused by this model and its limited availability, it is rarely used 
to model hyperuricemia.  
1.6.3 Glut 9 Knockout 
Glut9, apart from being an important UA transporter in the kidney, also plays an important role in the 
Uox mediated UA metabolism in rodents. Glut9 mediates the transport of UA across hepatocyte cell 
membranes. Systemic KO of Glut9 in mice leads to a dual phenotype caused by loss of function of both 
kidney and hepatic Glut9 [167]. Loss of function of hepatic Glut9 leads to hyperuricemia because 
plasma UA is unable to cross the hepatocyte cell membrane and cannot be metabolized by the 
intracellular Uox. Loss of function of the renal Glut9 transporter leads to a near total inability of renal 
urate reabsorption and thus massive uricosuria. These two mechanisms augment each other: 
Hyperuricemia is caused by the hepatic loss of Glut9 function leading to uricosuria, which is massively 
increased by the loss of urate reabsorption due to loss of renal Glut9 function. This leads to an extreme 
UA nephropathy with massive intraluminal UA crystal deposition [167].  
The hyperuricemia mouse model used in this work is an inducible, liver specific, Glut9 knockout that 
was generated by Preitner et. al. [168]. This model is generated using a floxed Glut9 gene and a cre 
recombinase that is expressed using the albumin promotor, making the expression of this enzyme liver 
specific as albumin is expressed exclusively in the liver. When the loss of function is desired, the cre 
can be activated by an i.p. injection of Tamoxifen leading to a knockdown of Glut9. The inducible nature 
of this phenotype means that hyperuricemia can be induced when a special diet is applied. Therefore, 
there is no perinatal mortality due to early onset kidney disease in these mice as seen in systemic Glut9 
or Uox KO mice. The phenotype of kidney disease and uricosuria is less severe than in systemic Glut9 
KO mice because the renal Glut9 mediated UA reabsorption is maintained in these mice thus making 
this model more physiological and better to study the effects of hyperuricemia. Hyperuricemia and 
kidney disease can be augmented in this model by feeding the mice inosine and a high fat diet. Inosine, 
a urate precursor, is metabolized to UA leading to a higher UA burden and plasma UA concentrations 
of around 8 mg/dl [168]. The high fat diet is used to augment kidney disease by decreasing urine pH 
and therefore increasing the likelihood of tubular UA crystalluria [168]. 
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2 Objectives and Experimental Strategy 
2.1 Objectives 
Chronic UA crystal nephropathy, defined as the presence of UA tophi in the kidney parenchyma, is a 
disease entity that has been controversy discussed in the past. It was previously assumed that kidney 
UA tophi cause kidney disease and are among the main reasons behind the widely observed 
association between hyperuricemia and CKD. However, after a series of publications casting doubt on 
the pathological relevance of medullary tophi [147, 153], the interest in this subject has tailed off and 
very little further research has been done in this field. Nevertheless, the entity of tophaceous UA 
nephropathy remains present throughout the literature and is often cited as a cause of CKD [169], as 
well as the relationship between asymptomatic hyperuricemia and CKD progression. Therefore, it 
remains to be elucidated whether asymptomatic hyperuricemia or UA crystal granulomas contribute 
to CKD progression. Previous reports focused only on statistical analysis to correlate markers of kidney 
injury to the presence of UA crystal granulomas. Currently, no animal model exists to investigate 
whether these asymptomatic hyperuricemia or hyperuricemia-related UA crystal granuloma causally 
contribute to the progression of CKD.  
The following objectives were set for this study: 
1. To characterize the histological abnormalities of diagnostic kidney biopsies with medullary UA 
crystal granulomas in a retrospective case-control study.  
2. To investigate whether hyperuricemia with UA crystal granuloma formation causes or 
contributes to CKD progression in a novel mouse model of chronic UA crystal nephropathy. 
3. To test whether asymptomatic hyperuricemia exacerbates preexisting CKD in mice. 
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2.2 Experimental Strategy 
Through a collaborator, a large series of kidney biopsy reports with described UA tophi and a series of 
control biopsies were acquired. These were statistically evaluated to look for a correlation between 
the presence of UA tophi and the extent of described interstitial kidney fibrosis and glomerular 
sclerosis, a very precise way to measure the extend of chronic kidney damage.  
To further study the pathogenesis of medullary gouty tophi in vivo, a reliable mouse model for this is 
first needed. Amongst the available and above described mouse models of hyperuricemia and UA 
crystal nephropathy, none have been able to reliably model tophaceous UA nephropathy. The UA 
nephropathy seen in all described models is attributed to the acute intraluminal precipitation of UA 
and is therefore similar to acute UA nephropathy seen in humans with tumor lysis or crush syndrome.  
The idea behind creating an in vivo model for tophaceous UA nephropathy was to obtain a mouse 
model with mild to moderate hyperuricemia and mild UA nephropathy. The model would be run over 
an extended period with monitoring the GFR until UA crystalluria-induced tubular obstruction 
progresses to CKD and enough time has passed for interstitial fibrotic transformation of the kidney to 
commence. These mice would be sacrificed at this point and the kidneys would be histologically 
examined for tophus formation. 
The choice fell upon the Alb-creERT2;Glut9lox/lox mouse [168]. Due to it being an inducible mouse 
model, there is no elevated perinatal mortality. After knockdown of Glut9 with tamoxifen, these mice 
remain healthy. Alb-creERT2;Glut9lox/lox mice fed a standard chow diet enriched with the UA precursor 
inosine develop asymptomatic hyperuricemia but without kidney disease. On the other hand, feeding 
Alb-creERT2;Glut9lox/lox mice an acidogenic diet supplemented with inosine results in hyperuricemia 
and UA crystalluria-associated CKD. The inducibility of both hyperuricemia (by feeding a chow diet with 
inosine) and tophaceous UA nephropathy with interstitial nephritis (by feeding an acidogenic diet with 
inosine) make this mouse model the correct choice for the attempt to create in vivo kidney UA tophi. 
The goal was to elucidate the pathogenesis of medullary gouty tophi: is kidney fibrosis a prerequisite 
for the formation of tophi or do tophi form in a hyperuricemic environment while kidney damage is 
just beginning? 
In order to further test this question, another animal model using aristolochic acid I was set up to 
induce non-crystalline CKD in mice, which were then made hyperuricemic to test if pre-existing fibrosis 
causes kidney tophi formation in a hyperuricemic environment. This experiment was also used to test 
whether hyperuricemia exacerbates preexisting CKD in mice. 
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3 Materials and Methods 
3.1 Materials 
3.1.1 Animal experiments 
Animals 
Alb-creERT2;Glut9lox/lox Mouse  Mouse Metabolic Facility, Lausanne, Switzerland 
Animal maintenance 
H-Temp Polysulfon Cage Eurostandard Typ II  Techniplast, Hamburg, DE 
Chow diet Ssniff Spezialdiäten GmbH, Soest, DE 
High fat diet Ssniff Spezialdiäten GmbH, Soest, DE 
High fat diet with inosine supplementation  Research Diets Inc., New Brunswick, USA 
Interior lattice cover Techniplast, Hamburg, DE 
Autoclavable filter hood Techniplast, Hamburg, DE 
Polycarbonate drinking bottles Techniplast, Hamburg, DE 
Mouse house red Techniplast, Hamburg, DE 
Litter of aspen wood Ssniff Spezialdiäten GmbH, Soest, DE 
Composition of standard Chow diet 
Ingredient Quantity  
Gross Energy 16.7 MJ/kg 
Metabolizable Energy 13.6 MJ/kg 
Dry matter 87.9 % 
Crude protein  22.0 % 
Crude fat 4.5 % 
Crude fiber 3.9 % 
Crude ash 6.8 % 
N free extracts 50.8 % 
Starch  34.0 % 
Sugar 5.0 % 
Calcium 1.00 % 
Phosphorus 0.70 %  
Sodium 0.24 % 
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Magnesium 0.21 % 
Potassium 1.02 % 
Vitamin A 25,000 IU/kg 
Vitamin D3 1,000 IU/kg 
Vitamin E 135 mg/kg 
Vitamin K (as menadione) 20 mg/kg 
Thiamin (B1) 86 mg/kg 
Riboflavin (B2) 32 mg/kg 
Pyridoxine (B6) 31 mg/kg 
Cobalamin (B12) 150 μg/kg 
Nicotinic acid 145 mg/kg 
Pantothenic acid 60 mg/kg 
Folic acid 10 mg/kg 
Biotin 700 μg/kg 
Choline-Chloride 3,130 mg/kg 
Inositol 100 mg/kg 
Inosine (only if chow diet included inosine 
supplementation) 
25.6 g/kg 
Composition of acidogenic diet 
Ingredient g% kcal% 
Protein  23 17 
Carbohydrate 35  26 
Fat  36 58 
Total   100 
kcal/g 5.6  
   
Ingredient g kcal 
Casein, 80 Mesh 228 912 
DL-M ethionine 2 8 
Maltodextrin 10 170 680 
Sucrose 175 700 
Soybean Oil 25 225 
Coconut Oil, Hydrogenated 333.5 3002 
Mineral Mix S10001 40 0 
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Sodium Bicarbonate 10.5 0 
Potassium Citrate, 1 H2O 4 0 
Vitamin Mix V10001 10 40 
Choline Bitartrate 2 0 
FD&C Red Dye #40 0.1 0 
Total 1000.1 5567 
Composition of acidogenic diet plus inosine 
Ingredient g% kcal% 
Protein 22 17 
Carbohydrate 35 26 
Fat  35 58 
Total   100 
kcal/g 5.4  
   
Ingredient g kcal 
Casein, 80 Mesh 228 912 
DL-Methionine 2 8 
Maltodextrin 10 170 680 
Sucrose 175 700 
Soybean Oil 25 225 
Coconut Oil, Hydrogenated 33.5 3002 
Mineral Mix S10001 40 0 
Sodium Bicarbonate 10.5 0 
Potassium Citrate, 1 H2O 4 0 
Vitamin Mix V10001 10 40 
Choline Bitartrate 2 0 
Inosin 26.3 0 
FD&C Blue Dye #1 0.05 0 
Total 1026.4 5567 
Inosin (g/kg) 25.6  
 
 
Materials and Methods 
 
27 
Blood extraction  
Glass capillaries 32 x 0,8 mm, not heparinized NeoLab Migge GmbH, Heidelberg, DE 
Isofluran Forene® Abbott, Wiesbaden, DE 
Eppendorf-Tubes 1,5 ml TPP, Trasadingen, CH 
Eppendorf-Tubes 2,0 ml TPP, Trasadingen, CH 
Genotyping 
DirectPCR® Lysis Reagent Tail PEQLAB Biotechnologie GmbH, Erlangen, DE 
Proteinase K Qiagen GmbH, Hinden, DE 
Quali-PCR-Tubes Kisker Biotech GmbH, Steinfurt, DE 
Taq DNA Polymerase New England BioLabs, Frankfurt, DE 
10X Standard Taq Reaction Buffer New England BioLabs, Frankfurt, DE 
Genotyping Primers metabion, Martinsried, DE 
dNTP Set Thermo Fisher Scientific Inc., Waltham, USA 
Agarose Invitrogen Ltd., Waltham, USA 
peqGREEN DNA/ RNA dye PEQLAB Biotechnologie GmbH, Erlangen, DE 
Low MW DNA Ladder New England BioLabs, Frankfurt, DE 
6X DNA Loading Thermo Fisher Scientific Inc., Waltham, USA 
Tris-HCl  Roth, Karlsruhe, DE 
Boric acid Sigma-Aldrich, Taufkirchen, DE 
Ethylene diamine tetraacetate (EDTA) sodium 
salt 
Merck, Darmstadt, DE 
Organ extraction 
RNAlater  Life Technologies, Darmstadt, DE 
Formalin, 4 %  Morphisto GmbH, Frankfurt, DE 
Embedding cassettes NeoLab, Heidelberg, DE 
Disposable scalpel No. 11 Feather Safety Razor Co. Ltd., JPN 
Intraperitoneal injection and oral gavage 
BD MicrolanceTM 3, 30G Becton, Dickinson, Franklin Lakes, USA 
BD PlastipakTM syringe Becton, Dickinson, Franklin Lakes, USA 
Natural oil (Mygliol®812) Sigma-Aldrich, Taufkirchen, DE 
Tamoxifen Sigma-Aldrich, Taufkirchen, DE 
Ethanol Merck, Darmstadt, DE 
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Aristolochic acid I Merck, Darmstadt, DE 
Phosphate buffered saline (PBS) PAN-Biotech GmbH, Aidenbach, DE 
Inosine Sigma-Aldrich, Taufkirchen, DE 
Polyethylene glycol (PEG) Merck, Darmstadt, DE 
Gavage needle Fisher Scientific UK Ltd, Loughborough, UK 
Measurement of glomerular filtration rate 
FITC-Sinistrin Fresenius Kabi, Bad Homburg, DE 
Leukoplast® hospital BSN medical GmbH, Hamburg, DE 
NIC-Kidney Patches 3x3cm MediBeacon GmbH, Mannheim, DE 
Rechargable batteries for NIC-Kidney devices MediBeacon GmbH, Mannheim, DE 
Transdermal GFR Monitor MediBeacon GmbH, Mannheim, DE 
Sterile gauze swab  Nobamed Paul Danz, Wetter, DE 
Isoflurane CP® CP-Pharma Handelsgesellschaft mbH, Burgdorf, 
DE 
3.1.2 Histology and microscopy 
Slides Thermo Fisher Scientific Inc., Waltham, USA 
Cover glasses for microscopy Thermo Fisher Scientific Inc., Waltham, USA 
Sodium acetate trihydrate Merck, Darmstadt, DE 
3,3’-Diaminobenzidine Merck, Darmstadt, DE 
Antigen Unmasking Solution Vector Laboratories, Burlingame, USA 
Avidin/Biotin Blocking Kit Vector Laboratories, Burlingame, USA 
Biotinylated Lotus Tetragonolobus Lectin Vector Laboratories, Burlingame, USA 
Acetic acid 99-100% Merck, Darmstadt, DE 
Coloring solutions containing hematoxylin Sigma-Aldrich, Taufkirchen, DE 
MACH 1 Universal HRP-Polymer Detection Biocare Medical, Concord, USA 
Skimmed milk powder Merck, Darmstadt, DE 
Methanol Merck, Darmstadt, DE 
Methyl green Sigma-Aldrich, Taufkirchen, DE 
Ethanol Merck, Darmstadt, DE 
Ammonium peroxodisulfate Carl Roth GmbH + Co. KG, Karlsruhe, DE 
Acetone Merck, Darmstadt, DE 
Direct Red 80 Sigma-Aldrich, Taufkirchen, DE 
Paraplast® for tissue embedding Merck, Darmstadt, DE 
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Xylol Fisher Scientific UK Ltd, Loughborough, UK 
Nuclear Fast Red solution Sigma-Aldrich, Taufkirchen, DE 
Periodic acid Carl Roth GmbH + Co. KG, Karlsruhe, DE 
Proteinase K Qiagen GmbH, Hinden, DE 
Hydrochloric acid Carl Roth GmbH + Co. KG, Karlsruhe, DE 
Schiff's reagent Sigma-Aldrich, Taufkirchen, DE 
Silver nitrate Carl Roth GmbH + Co. KG, Karlsruhe, DE 
VectaMount Permanent Mounting Medium Vector Laboratories, Burlingame, USA 
VECTASTAIN® Elite®ABC-HRP Kit Vector Laboratories, Burlingame, USA 
Hydrogen peroxide Carl Roth GmbH + Co. KG, Karlsruhe, DE 
Rasburicase EBiosciences, San Diego, USA 
3.1.3 Analytical methods 
RNA isolation 
2-Mercaptoethanol Sigma-Aldrich, Taufkirchen, DE 
Lysing Matrix D, 2 mL Tube MP Biomedicals, Eshwege, DE 
PureLinkTM RNA Mini Kit  Life Technologies, Carlsbad, USA 
Ethanol 96% Merck, Darmstadt, DE 
Falcon® 5ml Polypropylene Round-Bottom Tube Corning Science, Kaiserslautern, DE 
RNase AWAY® Sigma-Aldrich, Taufkirchen, DE 
RNase-Free DNase Set Qiagen GmbH, Hinden, DE 
Distilled water (DNAse/RNase free) GIBCO/Invitrogen, Paisley, Scotland, UK 
Reverse transcription 
Strand Buffer Thermo Fisher Scientific Inc., Waltham, USA 
0.1 M DTT Thermo Fisher Scientific Inc., Waltham, USA 
RNasin® Ribonuclease Inhibitor Promega GmbH, Walldorf, DE 
dNTP Set Thermo Fisher Scientific Inc., Waltham, USA 
Hexanucleotide Mix Roche Diagnostics, Basel, CH 
Linear Acrylamide Thermo Fisher Scientific Inc., Waltham, USA 
SuperScriptTM III Reverse Transcriptase Thermo Fisher Scientific Inc., Waltham, USA 
qPCR 
10X Taq Buffer Thermo Fisher Scientific Inc., Waltham, USA 
Optically clear adhesive film Sarstedt AG & Co. KG, Nümbrecht, DE 
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BioStab PCR Optimizer Biomol GmbH, Hamburg, DE 
96 Well Lightcycler Plate Sarstedt AG & Co. KG, Nümbrecht, DE 
SYBR® Green I nucleic acid gel stain Sigma-Aldrich, Taufkirchen, DE 
Bovine Serum Albumin, PCR grade Thermo Fisher Scientific Inc., Waltham, USA 
Taq DNA Polymerase New England BioLabs, Frankfurt, DE 
MgCl2 25mM Thermo Fisher Scientific Inc., Waltham, USA 
dNTP Set Thermo Fisher Scientific Inc., Waltham, USA 
PCR primers Metabion, Martinsried, DE 
Primer List 
18s RNA Forward     5‘-GCAATTATTCCCCATGAACG-3‘ 
Reverse     5‘-AGGGCCTCACTAAACCATCC-3‘ 
KIM-1 Forward    5‘-TCAGCTCGGGAATGCACAA-3‘ 
Reverse     5‘-TGGTTGCCTTCCGTGTCTCT-3‘ 
Il6 Forward    5’-TGATGCACTTGCAGAAAACA-3’ 
Reverse     5’-ACCAGAGGAAATTTTCAATAGGC-3’ 
Tnfα Forward    5‘-CCACCACGCTCTTCTGTCTAC-3‘ 
Reverse     5‘-AGGGTCTGGGCCATAGAACT-3‘ 
Collagen1α1 Forward    5‘-ACATGTTCAGCTTTGTGGACC-3‘ 
Reverse     5‘-TAGGCCATTGTGTATGCAGC-3‘ 
Fibronectin-1 Forward    5‘-GGAGTGGCACTGTCAACCTC-3‘ 
Reverse     5‘-ACTGGATGGGGTGGGAAT-3‘ 
FSP-1 Forward    5‘-CAGCACTTCCTCTCTCTTGG-3‘ 
Reverse     5‘-TTTGTGGAAGGTGGACACAA-3‘ 
Photometric Methods 
QuantiChromTM Uric Acid Assay Kit BioAssay System, Hayward, USA 
Urea FS DiaSys GmBH, Holzheim, DE 
Creatinine FS DiaSys GmBH, Holzheim, DE 
96F microwell plate without lid Thermo Fisher Scientific Inc., Waltham, USA 
Flow cytometry 
Zombie NIRTM Fixable Viability Kit BioLegend, Fell, DE 
FBS Biochrom GmbH, Berlin, DE 
Nykodenz  Axis-Shield Diagnostics Ltd., Dundee, GBR 
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PBS PAN-Biotech GmbH, Aidenbach, DE 
Collagenase (Clostridium histolyticum) Sigma-Aldrich, Taufkirchen, DE 
DNase I Sigma-Aldrich, Taufkirchen, DE 
Pre-Seperation Filter (70 mm) Miltenyi Biotec GmbH, Bergisch Gladbach, DE 
BSA Fraction V Roche Diagnostics, Basel, CH 
Sodudium azide Carl Roth GmbH + Co. KG, Karlsruhe, DE 
AccuCheck Counting Beads Thermo Fisher Scientific Inc., Waltham, USA 
AbCTM Anti-Rat/Hamster Bead Kit Thermo Fisher Scientific Inc., Waltham, USA 
Antibodies for flow cytometry 
PE/Cy5 linked anti-mouse CD45 BioLegend, Fell, DE 
V450 linked anti-mouse CD11b BioLegend, Fell, DE 
FITC linked anti-mouse CD206 BD Biosciences, DE 
PE/Cy7 linked anti-mouse CD11c BioLegend, Fell, DE 
PE/Cy7 linked anti-mouse Gr-1 BioLegend, Fell, DE 
BV510 linked anti-mouse MHCII BioLegend, Fell, DE  
PE linked anti-mouse CX3CR1 BioLegend, Fell, DE 
PE/Cy7 linked anti-mouse Ly6C  BioLegend, Fell, DE 
FITC linked anti-mouse Ly6G BioLegend, Fell, DE 
APC linked anti-mouse CD4 BioLegend, Fell, DE 
PE linked anti-mouse CD8 BioLegend, Fell, DE 
APC linked anti-mouse F4/80 Bio-Rad Laboratories, Inc., Hercules, USA 
Zombie NIR viability dye BioLegend, Fell, DE 
3.1.4 Instruments and devices 
Non-disposables 
Flow cytometer BD FACS Canto II BD Biosciences, Heidelberg, DE 
Electrophoresis chamber Mini-PROTEANR Tetra 
System 
Bio-Rad Laboratories, Inc., Hercules, USA 
PowerPac 300 electrophoresis power supply Bio-Rad Laboratories, Inc., Hercules, USA 
Microwave  Severin, Sundern, DE 
GENios Plus Elisa reader Tecan, Männedorf, CH 
Real-Time PCR-System LightCycler 480 Roche Diagnostics, Basel, CH 
Homogenizer ULTRA-TURRAXR T 25 basic IKA® -Werke GmbH & Co. KG, Fulda, DE 
Thermomixer 5436 Eppendorf AG, Hamburg, DE 
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Modular paraffin pouring station EC 350 Microm International GmbH, Dreieich, DE 
Spektrophotometer NanoDrop 1000 Thermo Fisher Scientific Inc., Waltham, USA 
Water bath 1013 GFL mbH, Burgwedel, DE 
Tube Roller SRT6 Stuart Equipment, Staffordshire, UK 
Centrifuge Megafuge 1.0R Heraeus Instruments, Hanau, DE 
Centrifuge 5415 C Eppendorf AG, Hamburg, DE 
Rocky-N rocker table Labortechnik Froebel GmbH, Lindau, DE 
Vortex-GenieTM 2 G-560-E Scientific Industries, Inc., Bohemia, USA 
Kryostat CM3000 Leica Biosystems, Wetzlar, DE 
Leica DMRBE Research Microscope Leica Microsystems, Wetzlar, DE 
Rotational microtome HM 340 E Microm International GmbH, Dreieich, DE 
Sterile workbench Microflow Biological Safety 
Cabinet 
Nunc GmbH, Langenselbold, DE 
Thermo-Cycler Mastercycler® pro Eppendorf AG, Hamburg, DE 
X-ray film developer Curix 60 AGFA, Mortsel, BEL 
SurgiVet vaporizer for florane Anesthetic Smiths Medical, Grasbrunn, DE 
Semi-Dry-Blotter Trans-Blot® SD Bio-Rad Laboratories, Inc., Hercules, USA 
Vertical rotator Bachofer GmbH & Co. KG, Weilheim, DE 
pH meter WTW  WTW GmbH, Weilheim, DE  
Multipipette Plus  Eppendorf AG, Hamburg, DE  
Research Pipette Plus 30 – 300 µl Eppendorf AG, Hamburg, DE  
Pipetman 2, 10, 20, 100, 200, 1000 μl Gilson, Middleton, US  
Pipetus classic  Hirschmann Laborgeräte, Eberstadt, DE 
Disposables 
Eppendorf tubes 1.5, 2.0 ml Eppendorf AG, Hamburg, DE 
Serological pipettes BD Biosciences, Heidelberg, DE 
Pipette tips 10 – 1000 µl Peske, Aindling-Arnhofen, DE  
Vacuum filtration system 150 ml, 500 ml TPP, Trasadingen, CH 
Falcon tubes 15, 50 ml BD Biosciences, Heidelberg, DE 
Needles 16, 18, 20, 22, 24, 26 G BD Biosciences, Heidelberg, DE 
Tissue culture dishes  TPP,Trasandigen, CH  
Ultra-cut  Leica Microsysteme, Wetzlar, DE 
Diskardit II syringe 1 ml, 2 ml, 5 ml  BD Biosciences, Heidelberg, DE 
Tweezers  Angiokard Medizintechnick, Freiburg, DE 
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SuperFrost Plus ™ adhesive slides Fisher Scientific GmbH, Schwerte, DE 
Pipette tips ep T.I.P.S  Eppendorf AG, Hamburg, DE  
ELISA 96-well plate  Thermo Fisher Scientific Inc., Waltham, USA 
X-ray films  Sigma-Aldrich, Taufkirchen, DE 
Embedding cassettes  ISOLAB, Wertheim, DE  
3.1.5 Software 
ImageJ Wayne Rasband, USA 
Prism Graph Pad, San Diego, USA 
Microsoft Excel Microsoft Corp., Redmond, USA 
Microsoft PowerPoint Microsoft Corp., Redmond, USA 
Microsoft Word Microsoft Corp., Redmond, USA 
SPSS 24 IBM, Armonk, USA 
3.2 Analysis of human biopsy reports  
3.2.1 Database search and acquisition of diagnostic biopsy reports 
The kidney biopsies at the Arkana Laboratories, Little Rock, were examined by experienced kidney 
pathologists using standardized methods. The tissue cylinder was fixed in Michel’s fixative or in 10% 
neutral buffered formalin. Sections were then stained with period acid-Schiff (PAS), hematoxylin and 
eosin (H&E) or silver stain according to standard protocol. Representative images were taken. The 
Arkana Laboratories archive up to June 2016 was searched with the key words: HU, gouty arthritis, UA 
tophi, UA urolithiasis and UA nephropathy and the presence of UA tophi on kidney biopsies. This search 
yielded 199 pathology reports from patients with UA-related pathologies (patients with medullary UA 
tophi that were found in the biopsy of patients with previously diagnosed hyperuricemia or 
hyperuricemia-related conditions). The biopsy reports were anonymized before being subjected to 
qualitative and quantitative case-control analysis. This study was approved by the local Ethics Board of 
the Medical Faculty at the Ludwig-Maximilians University Munich, Germany (17-588 UE).  
The aim of my study was to examine the influence of kidney tophi on histological-morphological 
features, such as interstitial fibrosis. Therefore, two groups were needed for the comparison. The 
experimental group consisted of 84 cases in which the examining pathologists found UA tophi. To allow 
for a retrospective case-control-study with equal group sizes, 84 cases were selected at random of the 
115 case reports with hyperuricemia (see section 4.1.1, Figure 11). A retrospective analysis was 
performed using these standardized kidney biopsy reports (84 cases with UA tophi versus 84 cases 
with hyperuricemia or hyperuricemia-related pathologies but without UA tophi).  
Materials and Methods 
 
34 
For statistical comparison of the diagnostic kidney biopsies with and without UA tophi, the biopsy 
reports were anonymized and then subjected to statistical analysis. Interstitial fibrosis and tubular 
atrophy, arterial and arteriolar nephrosclerosis were evaluated and scored by the pathologists as 
absent (<5% of area involved), mild (6-25% of area involved), moderate (26-50% of area involved), or 
severe (>50% of area involved) [170]. To assess the ratio of glomerulosclerosis between the two 
groups, the number of globally sclerosed glomeruli was divided by the total number of glomeruli 
present. UA crystal deposits appeared as empty spaces in form of needle shaped or feathery clefts 
representing dissolved UA crystals after formalin fixation and tissue processing.  
3.2.2 Statistical evaluation and comparison of the groups 
An Excel table was generated in which all variables were recorded for all cases. Examples include sex, 
age, grading of interstitial fibrosis, serum creatinine (if reported), etc. From this an SPSS document was 
produced in which the variables were numerically coded for all cases and were thus ready for statistical 
analysis. The Mann-Whitney-U test was used to compare metric data. The χ2 test for trend was used 
to compare ordinally scaled data. The χ2-test was used to compare nominally scaled data. If nominal 
data was present on a 2x2 spread, Fisher's exact test was used. An α = 0.05 was assumed. The term 
"significant difference" in the text of this work is equivalent to its statistical meaning. In the graphics, 
the p-value is abbreviated as follows: p <0.05 with "*", p <0.01 with "**", and p <0.001 with "***". 
3.3 Animal experiments  
3.3.1 Animal housing and care 
The experimental animals used in the present work were exclusively mice, obtained from a 
collaborator, the Mouse Metabolic Facility in Lausanne, Switzerland, and then bread to acquire the 
desired genetic background in our laboratory. The genetic modification used in this model were 
created and described by Preitner et. al [168] in a C57BL/6N genetic background. The mice were judged 
healthy based on FELASA recommendations [171].  
The provisions of the German Animal Welfare Act (Tierschutzgesetz) were always applied during the 
experiments. All animal experiments used were explicitly approved by the government (Regierung von 
Oberbayern) prior to the study (AZ: ROB-55.2-2532.Vet_02-15-189) or II LKE in Krakow (reference 
number: 70/2018, 257/2018) based on the EU directive for the Protection of Animals Used for Scientific 
Purposes (2010/63/EU) and reported according to the ARRIVE guidelines [172]. 
The mice were kept in groups of up to 5 animals inside polypropylene and cellulose cages containing a 
red plastic mouse house and aspen wood litter. The mouse facility was kept at 22±2°C and a 12-hour 
light / dark cycle. Water and standard chow (ssniff-Spezialdiäten GmbH) was available to the animals 
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ad libitum. The cages of the mice were changed once a week by a trained laboratory animal keeper. 
Cages, lids, bedding, houses, iron inlays, food, and water (ddH2O) were sterilized by autoclaving at 
120°C and 1 bar pressure for 20 minutes. The transfer of the animals into fresh cages procedures on 
the animals were carried out under sterile conditions.  
3.3.2 Mouse model of chronic uric acid nephropathy  
The Alb-creERT2;Glut9lox/lox mice were created and kindly provided by Frederic Preitner and Bernhard 
Thorens from the Center of Integrative Genomics in Lausanne, Switzerland [167, 168]. These mice 
contain a genomically integrated albumin promotor (Alb) that set is before the exon sequences of a 
cre recombinase coupled with an estrogen receptor (ERT2). Albumin is the most abundant serum 
protein and its function is the creation and maintenance of intravascular oncotic pressure and the 
blood transport of low molecular substances. Albumin is expressed exclusively in the liver, leading to 
a liver-specific expression of cre and ERT2 in these mice. Cre is an enzyme that recognizes and cuts 
loxP sites in the genome. In this mouse model, cre is attached to the estrogen receptor ERT2, keeping 
the recombinase outside of the nucleus. When knockout induction is desired, tamoxifen is given. 
Tamoxifen binds to ERT2, leading to conformational changes within the protein, allowing the 
compound protein to enter the nucleus, where the cre recombinase can cut the loxP sites in the DNA. 
In this mouse model, the Glut9 is flanked by two loxP sites that act as a DNA recognition pattern for 
the cre recombinase. Glut9 is a transmembrane channel for UA that is used in the liver by mice to 
internalize UA for enzymatic degradation. Glut 9 is not a liver specific protein; in the mouse kidneys it 
is used to reabsorb UA. Due to the presence of the albumin promoter before the cre-ERT2 protein 
complex, the knockout is liver specific and does not have systemic consequences. Figure 5 provides a 
graphic overview. 
 




Figure 5. The Alb-creERT2;Glut9lox/lox mouse explained 
The Alb-creERT2;Glut9lox/lox mouse is created by crossing an Alb-creERT2 mouse with a Glut9lox/lox mouse and 
breeding until the desired genotype (homozygous Alb-creERT2(ki/ki);Glut9lox/lox) is created. The liver specific 
Glut9 knockout remains dormant until tamoxifen is injected into the mouse. Once tamoxifen is administered, the 
cre recombinase is able to cross the nuclear membrane and cut the DNA double strand at the loxP sites, leading 
to a loss of the Glut9 gene and the activation of the knockout. Modified after https://www.jax.org/news-and-
insights/jax-blog/2011/september/cre-lox-breeding [173]. 
 
The Alb-creERT2;Glut9lox/lox mice were intraperitoneally (i.p.) injected with tamoxifen at around 5 
weeks of age. Tamoxifen was administered a total of three times every alternate day, with a daily dose 
of 1 mg. The tamoxifen crystals (Sigma-Aldrich) were weighed out to 15 mg on a microscale inside a 15 
ml Falcon tube. The 15 mg of tamoxifen was then dissolved in 150 µl of 99.9% Ethanol and 1,350 µl of 
natural oil (Mygliol®812). This made a solution with a total volume of 1,500 µl and 1 mg of tamoxifen 
per 100 µl. Each mouse received 100 µl of this solution per injection.  
To investigate whether UA crystal deposits can trigger acute uric acid crystal nephropathy, Alb-
creERT2;Glut9lox/lox and Glut9lox/lox control mice were injected with tamoxifen to knock out Glut9 in 
hepatocytes and placed on an acidogenic diet (ACD) for 6 weeks. On day 42, 43, and 44, both groups 
of mice received an oral administration of the precursor inosine [168].  
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Figure 6. Experimental Timeline 
On Monday, Wednesday, and Friday of week 0, the mice received an i.p. injection of either 15mg tamoxifen or 
the natural oil/ethanol vehicle. On Monday of week 1, the diet was changed to a acidogenic diet in the ACD 
groups. On Monday of week 4, daily gavage of 40mg of inosine was started. On Sunday of week 6, the mice were 
sacrificed and the experiment was ended. 
 
3.3.3 Aristolochic acid mouse model  
Aristolochic acid (AA) was used to induce CKD in Alb-creERT2;Glut9lox/lox and Glut9lox/lox control mice 
before making them hyperuricemic. The experiments using AA in mice were kindly performed by 
Maciej Lech in Krakow, Poland (reference number of approved animal clearance: 70/2018, 257/2018). 
As described in section 1.1.1, AA causes rapid progressive tubular necrosis and fibrosing interstitial 
nephritis. In a very short period, the mice develop relevant amounts of kidney fibrosis. AA was 
administered a total of six times every alternate day as described in Honarpisheh et. al [35]. 
Aristolochic acid I (AAI) was dissolved in 500 µl D-PBS and injected at 5 mg/kg bodyweight. The control 
group received injections of the D-PBS vehicle without the dissolved AAI salt. AA was administered via 
intraperitoneal injection every other day for a total of 6 injections.  
Experimental setup and timeline 
The relationship between hyperuricemia and CKD were investigated in three experimental groups. The 
phenotypes were distributed amongst the three groups as followed: CKD and asymptomatic 
hyperuricemia (HU) were induced in Group A, only CKD was induced in group B, and only asymptomatic 
hyperuricemia was induced in group C. HU was created using Alb-creERT2;Glut9lox/lox genetic 
background described in the previous section and induced a total of three 1 mg i.p. injections of 
tamoxifen every other day. CKD was induced by i.p. injections of 5 mg/kg of aristolochic acid I salt in 
D-PBS a total of six times every alternate day. Mice in group B carried only a floxed Glut9 gene but no 
cre recombinase (+/+ Glut9lox/lox), therefore the knockout was not induced upon tamoxifen injection 
and the mice remained normouricemic. Mice in group C received only the D-PBS vehicle per i.p. 
injection without AAI. Figure 7 gives an overview of the experimental setup and the phenotypes of the 
three groups. Baseline blood was collected before the phenotype induction with AAI and tamoxifen 
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and on day 42 shortly before mouse sacrifice. The measurement of GFR was performed at baseline 
(before phenotype induction), on day 21 and 42.  
Alb-cre ERT2 Glut9lox/lox 
Glut9lox/lox 
Alb-cre ERT2 Glut9lox/lox 
Injection of 6x AAI / 3x Tamoxifen
Injection of 6x AAI / 3x Tamoxifen
Injection of 6x D-PBS Vehicle / 3x Tamoxifen




Day 1: Start of
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Figure 7. Experimental setup and timeline 
(a) Group A (HU + CKD): The Alb-creERT2;Glut9lox/lox mice received a total of six i.p. injections of AAI (5 mg/kg) to 
induce CKD and a total of 3 i.p. injections of tamoxifen to induce hyperuricemia (HU). (b) Group B (CKD only): The 
mice carried +/+ Glut9lox/lox background and received total of six i.p. injections of AAI (5 mg/kg) to induce CKD 
and a total of 3 i.p. injections of tamoxifen without inducing the Glut9 knockout due to a missing Alb-creERT2 
recombinase. (c) Group C (HU only): The Alb-creERT2;Glut9lox/lox received three injections of 100mg tamoxifen to 
induce hyperuricemia and 6 i.p. injection of the D-PBS vehicle without AAI. Inosine enriched chow diet was 
started on day 1 of the experiment. The mice were sacrificed on day 42.  
 
 
3.3.4 Breeding and genotyping 
Mice were kept as Alb-creERT2;Glut9lox/lox (ki/ki)and Glut9lox/lox (+/+) mice. In preparation of the mouse 
experiments, mice had to be bread to the desired genotype (Alb-creERT2;Glut9lox/lox). Several 
generations of breeding were required to obtain homozygous Alb-creERT2;Glut9lox/lox  and Glut9lox/lox 
(without cre) mice to start an experiment. Genotyping for both genes cre and Glut9 loxP was required 
in all mouse pups. The inheritance of both genes followed simple Mendelian principles.  
Genotyping is performed using a polymerase chain reaction (PCR). The principle of PCR is to reproduce 
a short section of DNA exponentially using a heat stable, DNA-dependent DNA polymerase (Taq 
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Polymerase). First, the free-floating double stranded DNA is denatured at 94°C. Secondly, the solution 
is cooled, allowing the abundantly added primers to attach to their complementary sequence 
(annealing), this step is performed at 59°C. In the third step, the Taq polymerase attaches to the 3’ end 
of the primer and extends the DNA strand complementary to the matrix strand. This final step is done 
at optimal reaction temperature for the polymerase, in this case at 72°C. The cycle is repeated 38 
times, leading to an amplification of x238 of the initial DNA strand. This highly copied piece of DNA can 
later be made visible, allowing conclusions to be made regarding its original quantity (qPCR) or 
presence (endpoint PCR). Table 2 shows the temperature program for the genotyping endpoint PCR. 
Table 2. PCR program for genotyping 
Program Initial DNA 
denaturation 
Denaturation Annealing Extension Cool down 




94 94 59 72 10 
 





Genotyping was kindly performed by Mrs. Janina Mandelbaum, a medical technical assistant in the 
Anders working group, as part of the routine genotyping of mice. Young mice, at an age of around 3 
weeks, received an ear puncture as a label during the breeding process. With this label, mice could be 
identified correctly for further breeding after genotyping was performed. The piece of ear tissue 
removed during labeling was used for PCR genotyping. The punched-out piece of tissue was either 
stored at -20°C or added directly to 150 µl Direct PCR Tail Peqgold (Peqlab) and 1 µl Proteinase K 
(Qiagen). This mixture was incubated inside a thermomixer for 3 to 4 hours at 55°C and 800 rpm until 
the tissue lysis was completed. Subsequent denaturation of proteinase K was achieved by a further 
incubation the solution at 85°C for 45 minutes. If processed within the next 24 hours, the lysate was 
stored at 4°C, otherwise it was stored at 20°C.  
An endpoint PCR was then carried out for both cre and the Glut9 loxP. For this purpose, a master mix 
shown in Table 3 was made for each reaction [174]. Each reaction consisted of 24 µl of the master mix 
and 1 µl of the Lysates and was prepared in 0.2 ml Quali-PCR tubes. The mixture was centrifuged briefly 
to make sure all the liquid gathers at the bottom of each tube and PCR was then performed under the 
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conditions given in Table 2 in a Mastercycler R (Eppendorf). The primers used for each reaction are 
shown in Table 5 and Table 6. 
Table 3. Master mix for the endpoint genotyping PCR of one sample 
Reagent Volume (µl) 
H2O 15.3 
10x PE Buffer 2.5 
11,25 mM dNTPs 4 
Forward primer  1 
Reverse primer 1 
Taq DNA Polymerase 0.2 
Total master mix 24 
Sample volume  1 
Total reaction volume (1 sample) 25 
 
The reaction product was made visible using gel electrophoresis. Here, the samples containing the 
amplified DNA were run across an agarose gel using a current. The negative charge of DNA caused the 
molecules to move through the gel toward the cathode, separating the DNA based on the length of 
the amplified product. To produce a 2% agarose gel, 3 g of agarose were weighed into an Erlenmeyer 
flask, 150 ml of 0.5 X TRIS-Borate-EDTA buffer (TBE buffer, Table 4) was added and the solution was 
heated in the a microwave until the agarose was completely dissolved. The solution was cooled to 
around 60°C inside the Erlenmeyer flask under running water. At this point, 12 µl of pegGREEN, an 
intercalating DNA dye, was added to the solution. The solution was then poured into the gel chambers, 
avoiding the formation of any air bubbles.  
Table 4. 5x TBE-Buffer 
Substance Concentration (mM) 
Tris (hydroxymethyl) aminomethane 890 
Ethylene diamine tetraacetate (EDTA) sodium salt 20 
Boric acid 890 
 
After 20-30 minutes the gel had hardened and was covered with TBE buffer and placed in the 
appropriate electrophoresis apparatus. 5 µl of 6X DNA Loading was added to the PCR product. 12 µl of 
this mixture were pipetted into the gel bag. Together with the samples, a standard DNA latter (Low 
MW DNA Ladder, New England Biolabs R Inc.), a positive and negative control were pipetted into 
adjacent gel bags. The DNA latter contains a mix of oligonucleotides with known length and is used to 
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approximate the base length of the PCR product. The electrophoresis was started using the 
electrophoresis power supply and run at 200V for 30 minutes. The separated PCR products were then 
made visible using a UV transilluminator and photographed.  










Table 7. Genotyping PCR Results 
Glut9 +/+ flox/+ flox/flox 
SL25/Sl29 341 bp 460 / 341 bp 460 bp 
SL25/SL26 1684 bp 1684 bp >2 kbp 
Alb-creERT2 +/+ ki/+ ki/ki 
ABT290/ABV93 229bp 229bp - 
ABT294/ABV93 - 444bp 444bp 
 
3.3.5 Procedures on mice 
Anesthesia 
Mice were anesthetized whenever a procedure causes unreasonable pain or stress. Mice were also 
anesthetized if a procedure required immobilization. This includes taking blood or shaving the back of 
mice before GFR measurement. Short-term isoflurane inhalation anesthesia was used exclusively in 
this project. Long-term anesthesia was possible in the laboratory, however for all procedures done in 
this project only a brief incapacitation of the mice was required. To anesthetize a mouse using 
isoflurane, the mouse was put into a closed anesthesia chamber and 3% isoflurane in oxygen (4 l/min) 
were passed into the chamber. Depending on the size and age of the mouse or the desired depth of 
anesthesia, the animal was left in the chamber for a few seconds to a few minutes. Afterward, the 
mouse was removed from the anesthesia chamber, the procedure was performed immediately, and 
the mouse placed back into the cage and observed until it completely woke up.  




Blood collection was done during the ongoing experiment and at the end, shortly before the mouse 
sacrifice.  When taking blood during an experiment, only drops of blood were collected by puncturing 
the tail vein. Care was taken that no more than 5% of the weight of the mouse was removed in blood. 
As the average mouse weighed around 25 g, no more than 1.25 g of blood was removed. The tail vein 
puncture was performed without anesthesia. The mouse was led into a small tube, which restricted its 
motions but allowed for an adequate supply of oxygen. When the tail was fixed to make excessive tail 
movement impossible, the tail vein was punctured with a 30G needle and the blood drops were 
collected in 1.5-ml Eppendorf tubes. After the blood was collected, the bleeding was stopped by 
applying pressure with a sterile gauze. At the end of an experiment, the mice were put into the 
isoflurane anesthesia chamber until a deep narcosis was achieved. Using a round glass capillary that 
was open on both sides, the retrobulbar venous plexus was punctured and the blood was collected in 
1.5- or 2.0-ml Eppendorf tubes. This way the maximum possible amount of blood was extracted, and 
the mice were euthanized before awakening from the anesthesia. The collected blood was allowed to 
coagulate for 1 hour at room temperature. Afterwards, the tubes were centrifuged at 10,000 g for 10 
minutes and the blood serum was pipetted into clean Eppendorf tubes. The red blood cells were 
discarded, and the serum stored for further processing at -20°C. 
Urine collection 
To calculate the urine UA to creatinine ratio, the UA and creatinine concentrations had to be 
determined in the urine. To collect the urine samples, the mouse was taken from the cage in a stress-
free and quiet environment under a laminar flow mouse handling hood. The mouse was put into the 
neck handle. A 1.5- or 2.0-ml Eppendorf tube was used as collecting vessel and held close to the mouse 
genitalia. Using the index finger, the mouse bladder was palpated and gently massaged until the mouse 
began to urinate into the Eppendorf tube. Once the bladder was empty, the mouse was returned into 
the cage. At the end of an experiment, the urine collection was performed after the mice were 
euthanized. Here, the bladder was identified after the abdomen of the sacrificed mouse had been 
opened. The bladder was then punctured using a syringe with a 30G needle and the remaining 
intravesical urine was aspirated and transferred into and Eppendorf tube. The sample tubes were 
labeled and stored at 20°C until further processing.  
Intraperitoneal injection 
For the mouse experiments in this project, tamoxifen and aristolochic acid had to be administered 
systemically. This was done via intraperitoneal injection. Before entering the mouse facility, the 
solution that was to be injected was put into the syringe. A 30G needle was put onto the syringe under 
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the exclusion of any air bubbles. The mouse was taken out of its cage under a laminar flow mouse 
handling hood in a quiet environment and put into a neck hold, exposing its abdomen. The needle was 
introduced into the abdomen in the right lower quadrant and the solution was injected. The injected 
mouse was watched a few minutes and then returned into the cage.  
Measurement of GFR 
The glomerular filtration rate (GFR) is a measurement of volume that is filtered by the glomeruli in a 
given timeframe. It is directly proportional to the number of functioning nephrons in an organism and 
therefore a very accurate measurement of kidney function. In humans, the GFR can be approximated 
using equations like the Cockcroft- Gault formula that takes age, sex, serum creatinine, race, and 
bodyweight into account. In experimental mice, the GFR can be calculated by optically measuring the 
elimination rate of sinistrin in the bloodstream transcutanously. Sinistrin is a compound that, similar 
to creatinine, is filtered in the glomerulus and neither reabsorbed nor secreted in the tubulus. For this 
measurement, sinistrin, coupled with Fluorescein isothiocyanate (FITC), a green fluorescent dye, is 
injected intravenously into the mouse. The relative intravenous concentration of FITC-sinistrin was 
measured using a miniaturized light signal sensor that consisted of a light-emitting diode (LED) and a 
photodetector that were equipped with blue or green bandpass filters. A removable battery pack 
provided a power source for the light signal sensor. 
To prepare for the measurement, the test animal was first subjected to inhalation anesthesia.  After a 
minute, the test animal was removed from the anesthesia chamber and the back hair at the level of 
the thorax was shaved using a commercially available disposable wet shave razor. The back area that 
was shorn was approximately 2.5x2.5 cm large. The light signal sensor was attached to its battery pack 
and it was made sure that the light began flashing. The sensor was then attached to the bare skin of 
the mouse using a windowed double-sided adhesive tape and additionally secured using a thin strip of 
leucoplast. This strip of leucoplast encompassed the thorax of the mouse once and care was taken that 
the shoulder girdle was free so as not to impair movement of the animal. Five minutes after the sensor 
began recording, the mice were injected with 120 mg/kg bodyweight FTIC-sinistrin solution 
intravenously. The mice were fixed with the same restrainer that was used for blood collection. The 
tail vein was sought out using a 1 ml syringe with a 30G needle around 100 µl of solution was 
administered intravenously. Afterwards, the mice were put into individual, freshly autoclaved cages, 
where they remained for around 90 minutes until the measurement was complete. The measured 
fluorescence curves were read on the PC using the MPD-Lab application. The drop in the fluorescence 
signal over time was used to calculate the plasma half-life of FITC-Sinistrin (Figure 6). The GFR was 
calculated using an empirically determined conversion factor, the mouse body weight (BW) and the 
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Figure 8. GFR fluorescence curve example of a healthy mouse. 
The curve shows the fluorescence intensity (y-axis) measured across time (x-axis). The fluorescence intensity 
correlates with the amount of sinistrin in the body. The half-life of sinistrin in the mouse body is calculated using 
a regression model of this fluorescence curve. The GFR of is then calculated using the determined half-life.  
 
Mouse euthanasia and removal of kidneys 
The mice were euthanized by cervical dislocation after the experiment was completed. If blood 
collection was needed, the mice were first anesthetized in the isoflurane chamber. After euthanasia, 
the abdomen was opened, and the kidneys were visualized and removed. The fibrous kidney capsule 
was removed gently by peeling using the fingers. The kidneys were photographed if needed and then 
divided into three parts using a scalpel as shown in Figure 9. The kidney poles for PCR analysis were 
put into an Eppendorf tubes with 0.5 ml RNAlater, a solution to protect RNA from enzymatic 
degradation, and then stored at -20°C. The central parts for histology were put into biopsy cassettes 
and immediately fixed in 4% formaldehyde. The kidney pole used for flow cytometry, labeled as FACS 
in Figure 9 was processed immediately as described in section 3.4.5. 







Figure 9. Kidney division for tissue analysis. 
The kidneys were cut transversely, a small section in the middle was processed for histological purposes. The 
larger pole caps were used for RNA isolation and qPCR or for FACS analysis.  
 
3.4 Analytical methods 
3.4.1 Analysis of RNA expression by qPCR 
A cell requires two large steps to create a protein from an exon sequence of DNA. The first step is the 
transcription of exon DNA to messenger ribonucleic acid (mRNA). This step is done by DNA dependent 
RNA polymerases. The completed mRNA travels from the nucleus into cytoplasm. Using cytoplasmatic 
protein complexes called ribosomes, the second step, translation, is performed. Translation is the 
decoding of mRNA sequence into a polypeptide chain. This polypeptide undergoes post-translational 
modification to form the final protein. Both transcription and translation are subjected to a large 
amount of regulatory processes that the cell uses to control its protein signature. Regulation of 
transcription happens to such a large extend that the amount of mRNA of a specific protein inside the 
cell correlates with the amount of protein that a cell generates from that mRNA. For this reason, revere 
transcription quantitative polymerase chain reaction (qPCR), which is a measurement of the cell’s 
expression a specific mRNA relative to a highly ubiquitous mRNA, is a commonly practiced laboratory 
method that allows the investigator to draw conclusions about the protein content of a cell or tissue. 
Three steps are required for the analysis of mRNA expression of a tissue: RNA isolation, reverse 
transcription, and finally, qPCR. 
RNA isolation 
All work described below was carried out on ice. Before RNA isolation, all surfaces, pipettes, racks, and 
other working materials were treated with RNase AWAY® for 20 minutes if possible and then cleaned 
with 70% ethanol. Work with 2-mercaptoethanol was carried out with appropriate protective clothing 
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under a fume hood. The RNA was isolated from the above described kidney pole using the PureLinkTM 
RNA Mini Kit (life technologies). The tissue piece stored at -20°C in RNAlater was transferred to a 2 ml 
Eppendorf tube, which already contained 1.5 ml of the kit's own lysis buffer containing 1% 2-
mercaptoethanol. Using the ULTRA-TURRAX R®, the kidney pole was homogenized into a fine liquid 
suspension for 30 seconds. If necessary, a second homogenization was carried out after 5 minutes. The 
rotor blade of the ULTRA-TURRAX R® was cleaned with 70% ethanol and then with ddH2O after each 
processed sample to avoid cross-contamination. 700 µl of the tissue suspension were pipetted into a 
fresh 1.5 ml Eppendorf tube containing 700 µl of 70% analytical alcohol and vortexed thoroughly for 
one minute. 700 µl of this mixture was applied to the PureLinkTM spin cartridge with integrated RNA-
capturing membrane and centrifuged at 12,000 g for 30 seconds. This was repeated until the entire 
sample had passed through the membrane. The RNA bound to the membrane was washed once with 
700 µl of wash buffer 1 by centrifugation at 12,000 g for 30 seconds. 500 µl of wash buffer 2 was added 
to the membrane and centrifuged at 12,000 g for 30 seconds. The membrane was washed a second 
time using 500 µl of wash buffer 2. The membrane was then dried by centrifuging at 12,000 g for 2 
minutes. The collecting container of the spin cartridge was exchanged for an RNase / DNase-free 1.5 
ml Eppendorf tube and 35 µl RNase-free water from the kit was pipetted onto the membrane. The spin 
cartridge was incubated for 1 min at RT to allow the water to absorb into the membrane. The RNA that 
was bound to the membrane was eluted in the water by centrifugation at 20,000 g for 2 minutes and 
collected in the Eppendorf tube. The purified RNA was either stored at -80°C or put on ice for 
immediate further processing. If possible, transcription to cDNA was initiated immediately after the 
RNA isolation to lower the risk of enzymatic RNA degradation.  
The quality and quantity of RNA extraction was tested using a NanoDrop 1000 spectrophotometer 
(Thermo Scientific). For this purpose, 1 μl of the sample was examined and the absorbance between 
220 and 350 nm was measured. The purity of the sample was estimated using the 260/280 nm ratio. 
Only RNA samples with a 260/280 ratio of 1.8 to 2.2 were considered pure enough and processed 
further. Most of the samples used in this project had 260/280 ratio values between 1.95 and 2.19. The 
NanoDrop also measured RNA concentrations. Samples with concentrations below 150 ng/ml also 
could not be adequately transcribed to cDNA and were discarded. Most RNA samples isolated for this 
project contained an RNA concentration of around 1.0 mg/ml.  
Reverse transcription to cDNA 
In the following step, the isolated RNA was transcribed into complementary DNA (cDNA) using a 
reverse transcriptase. cDNA is less vulnerable to enzymatic degradation than RNA. Therefore, this step 
was usually done immediately following the isolation of RNA. The eluted RNA of all samples was dilated 
with RNase free water to a standardized concentration of 0.133 µg/µl. These dilutions were treated in 
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a thermocycler (Mastercycler® pro, Eppendorf) for 10 minutes at 65°C to linearize the RNA. Afterwards 
the tubes were immediately cooled on ice to 4°C and the master mix for the reverse transcription 
reaction was prepared. The master mix consisted of randomized hexanucleotide primers, an equimolar 
deoxyribonucleoside triphosphate mix (dNTPs), a reverse transcriptase with its corresponding buffer, 
an RNase inhibitor, acrylamide and dithiothreitol (DTT).  Table 8 shows the composition of the master 
mix for the reverse transcription reaction of one RNA sample [174]. RT (-) controls were made for each 
sample using same reagents but without SuperScriptTM II Reverse Transcriptase, and in its place the 
same quantity of ddH2O. This control was used to make sure no relevant amount of contamination is 
present in the qPCR samples that could falsify the result. 
Table 8. Master mix for the reverse transcription of mRNA to cDNA of one reaction 
Reagent Volume (µl) 
RNasin® Ribonuclease Inhibitor 0.5 
Hexanucleotide Mix 0.25 
dNTPs (25mM each) 0.45 
5x First Strand Buffer 4.5 
SuperScriptTM II Reverse Transcriptase 0.5 
Acrylamid 15 mg/ml 0.25 
DTT 0.1 M 1.0 
Total master mix 7.45 
Sample volume (0.133 µg/µl) 15 
Total reaction volume (1 sample) 22.45 
 
 
After the master mix was completed, 15 µl of diluted RNA (a total of 2 µg) were added to 7.45 µl of 
master mix inside Quali-PCR tubes. The reaction was started in a Mastercycler® pro (Eppendorf) at the 
conditions described in Table 9 and the final product was stored at -20°C for further processing.  
Table 9. Thermocycler conditions for reverse transcription reaction in Thermocycler 
Program Reverse transcription Reaction termination Cooling 
Repetitions 1 1 1 
Target temperature 
(°C) 
42 85 4 
Duration 120 5 Until temp is reached 
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Quantitative polymerase chain reaction 
A LightCycler 480 Real-Time PCR system (Roche Diagnostics) using a 96-well plate format was used to 
quantify the mRNA transcripts of specific target genes in the mouse kidney. This method enables the 
kinetic quantification of PCR product double strands with the help of the DNA-intercalating green 
fluorescent dye SYBR® Green I. The emission intensity of SYBR Green forms an exponential curve that 
emerges from the background earlier the more template cDNA is present. The emission intensity for 
each sample is determined by the device at the end of each cycle. The cDNA transcribed from mouse 
kidney RNA serve as templates for the PCR.  3 µl of the previously prepared cDNA was diluted in 126.6 
µl RNase and DNase free ddH2O. Of this diluted cDNA solution, 8.64 µl (corresponding to 0.2 µl 
undiluted cDNA) were used for one qPCR reaction. For the creation of the master mix, the SYBR Green 
pre-master mix solution first had to be made. Care was taken that enough of this solution was made 
to make the gene specific master mix in the next step. Table 10 shows the reagents used to make the 
pre-master mix solution. 
Table 10. SYBR Green pre-master mix solution 
Reagent  Volume (ml) 
PCR Optimizer 30 
10X Taq Buffer without Detergent 15 
MgCl2 25mM 18 
ddH2O 9.075 
BSA, PCR grade 1.5 
dNTPs (25mM je Base) 1.125 
SYBRR Green I 0.3 
Total 75 
 
Once the pre-master mix solution was made, the gene specific master mix was prepared. Table 11 
shows its protocol of preparation for one reaction. The process of making SYBR Green pre-master mix 
followed by a gene specific master mix was first described in [174]. 
Table 11. Gene specific master mix solution for one reaction 
Reagent Volume (µl) 
Pre-master mix 10 
Taq DNA Polymerase 0.16 
Forward primer 10 mM 0.6 
Reverse primer 10 mM 0.6 
Total 11.36 




The qPCR was planned on a 96 well plate in silico. The cDNA samples were distributed to one per two 
columns and the genes were distributed to one per row, allowing each sample to have two reactions 
with each gene primer (duplicates), always including one row with the 18S rRNA gene primer. The RT 
(-) samples distributed similarly but without duplicates. The expression of each gene was later 
determined relative to the expression of this “housekeeper” 18S rRNA, as this highly ubiquitous rRNA 
is expressed by cells at constant rates in all tissues. The design was then carried out on the 96 well 
qPCR plate. For each reaction, 8.64 µl of diluted sample and 11.36 µl of gene specific master mix was 
added to one well. After sealing the 96-well Lightcycler plate with a suitable transparent adhesive film 
(Sarstedt), the plate was centrifuged at 500 g for 30 seconds. The reaction was then carried out in the 
LightCycler 480 as shown in Table 12. 







1 95 5 min 
Denaturation 
40 
95 15 s 
Annealing 60 15 s 
Extension 68 20 s 
Melting curve 1 65 to 95 n.a. 
Cool down 1 40 30 s 
 
The quality of each reaction was checked by melting curve analysis. Only samples with a single clearly 
defined temperature peak were used for crossing point (CP) analysis. The RT (-) controls were checked 
to make sure no relevant PCR product emerged. The crossing point was determined by the LightCycler® 
480 software for each reaction and is equal to the maximum of the second derivative of the 
exponential fluorescent curve. It corresponds to the cycle number in which the fluorescence signal 
emerges from the background. Using the mean CP of the duplicates of the target gene and the 18S 
rRNA, the relative expression of each gene was calculated for each sample using the formula below. 
This formula assumes that the PCR product doubles in every cycle. 
𝑅𝑒𝑙𝑎𝑡𝑖𝑣𝑒 𝑚𝑅𝑁𝐴 𝑒𝑥𝑝𝑟𝑒𝑠𝑠𝑖𝑜𝑛 = 2−(𝐶𝑃 18𝑆 − 𝐶𝑃 𝑇𝑎𝑟𝑔𝑒𝑡 𝐺𝑒𝑛𝑒) 
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3.4.2 Measurement of creatinine 
Creatinine is a metabolic end-product that is produced in muscular tissue by degradation of creatine 
phosphate. It is released at constant rates by the muscle, depending on the overall muscle mass.  
Creatinine is eliminated by the kidney and can be used as a parameter for kidney function. Creatinine 
is suitable for this because it can only be eliminated by the kidney, it is filtered freely in the glomerulus 
and it undergoes virtually no tubular secretion or reabsorption. Creatinine was measured with the Jaffe 
reaction using the Creatinine FS (DiaSys) kit. The Jaffe reaction is a colorimetric approach to measuring 
creatinine. The test sample containing creatinine is exposed to picric acid in an alkaline environment, 
leading to the formation of creatinine picrate complexes, which induce an orange-red color change 
that is proportional to the concentration of creatinine in the sample. The kit included a creatinine 
standard that was used to create a linear standard curve. This standard was tested at different volumes 
(0, 5, 10, 15, and 20 µl), using ddH2O to compensate volume differences for the standard reactions. A 
picric acid containing standard master mix was created using four parts of reagent 1 and one part of 
reagent 2, both of which were supplied with the kit. Each sample was added at 10 µl per well to a 96 
well plate in duplicates. Using a multi-channel pipette, 200 µl of the standard mast mix was added to 
each well, commencing the reaction. The absorption was measured at 492 nm wavelength after an 
incubation time of 60 seconds and a second time after and 120 seconds. To analyze the data, the 
absorption at 60 seconds was subtracted from the absorption at 120s for all samples and standards 
and the means of all duplicates were calculated. A standard curve was creating using linear regression 
of the absorption differences of the standard samples. Using this best fit line, the concentration of 
creatinine in mg/dl was calculated for each sample. 
3.4.3 Measurement of blood urea nitrogen 
Serum blood urea nitrogen (BUN) was measured in experimental mice as an additional analytical 
method to approximate kidney function in this project. Urea, similar to creatinine, is a metabolic end 
product that must be eliminated by the kidney. Urea is created via the urea cycle from the highly toxic 
ammonia (NH3). Urea is used by cells as a vehicle to eliminate nitrogen that falls on in protein 
metabolism. Unlike creatinine, urea does undergo tubular secretion and reabsorption in relevant 
quantities. However, urea is more sensitive to small changes in kidney function as it does not have a 
“blind area”. BUN was measured indirectly via a double enzymatic conversion using the Urea FS DiaSys 
kit. The urea in the sample is split in the first reaction by urease into ammonium ions and hydrogen 
carbonate. In the second step, α-ketoglutarate is aminated using the ammonium ions created in the 
first reaction by a glutamate dehydrogenase using the redox partner NADPH. The decrease in NADPH 
concentration can be measured photometrically as a decrease in absorption at 340 nm, which is 
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proportional to the amount of urea in the sample. The samples were measured undiluted and analyzed 
according to the manufacturer protocol.  
3.4.4 Measurement of uric acid 
The UA concentration was measured in the serum as a functional parameter to check knockout 
induction and to approximate the UA burden of Alb-creERT2;Glut9lox/lox mice. It was also measured in 
the urine to form a urine UA to creatinine ratio as a measurement of the extend of uricosuria. Section 
1.2 gives an overview of UA metabolism and hyperuricemia. UA concentration in liquid samples 
measured using the QuantiChromTM Uric Acid Assay Kit (BioAssay Systems). The assay contains iron 
(Fe3+) ions that are reduced to iron (Fe2+) ions in the presence of UA. Fe2+ forms a blue colored complex 
with 2,4,6 - tripyridyl-s-triazine that can be measured photometrically at 590 nm. The absorption is 
linearly proportional to the concentration of UA in the sample. The serum samples were measured 






𝐴𝑏𝑠𝑜𝑟𝑝𝑡𝑖𝑜𝑛 𝑠𝑎𝑚𝑝𝑙𝑒 − 𝐴𝑏𝑠𝑜𝑝𝑡𝑖𝑜𝑛 𝑏𝑙𝑎𝑛𝑘
𝐴𝑏𝑠𝑜𝑟𝑝𝑡𝑖𝑜𝑛 𝑠𝑡𝑎𝑛𝑑𝑎𝑟𝑑 − 𝐴𝑏𝑠𝑜𝑟𝑝𝑡𝑖𝑜𝑛 𝑏𝑙𝑎𝑛𝑘
∗ 10𝑚𝑔/𝑑𝑙 
3.4.5 Flow cytometry 
Flow cytometry is a method in which cells are characterized by phenotype, size and granularity. The 
cells are sucked through a narrow microchannel and separated into a single file. The cells are then 
illuminated by laser beams at different wavelengths and the emission values are assessed using a 
detector. The forward scattered light (forward scatter) is proportional to the size of the cell, the larger 
diameter of the scattered light, the larger the cell. The side scatter light allows an assessment of cell 
granularity and cell surface. The more light is scattered sideways, the more uneven the surface and 
the higher the granularity of the cell. Additionally, cell surface markers or even intracellular proteins 
can be detected via labeling with antibodies that are conjugated to fluorescent markers. Depending 
on the flow cytometer, varying amount fluorescent dyes can be detected. Figure 10 gives an overview 
of the function of a flow cytometer. Flow cytometry was used in this project to precisely determine 
the composition of the intrarenal immune cell populations. A FACSCanto II (BD Biosciences) flow 
cytometer was used in this project. The following flow cytometry protocol was first described in [174]. 







Figure 10. Simplified principle of flow cytometry 
The cell suspension is sucked into a microchannel, creating a single file of cells. The laser beam scans each cell 
individually. The forward and side scatter are determined by individual sensors, providing information about the 
size, granularity and texture of the cell. Fluorescent labeling of the cell is also detected using this laser.  
 
Sample preparation for flow cytometry 
The kidneys were harvested as shown in Figure 9. The piece intended for flow cytometry was put into 
2 ml digestive buffer, consisting of 8 mg collagenase and 2000 IU DNase I in PBS. Using the plunger of 
a 2 ml syringe, the tissue was carefully ground into small pieces. This suspension was incubated at 37°C 
for 40 minutes. In order to create single cell suspension, the pretreated tissue was passed several times 
through a 20G and later a 25G needle using a syringe. Finally, the suspension was passed through a 
mesh filter with a pore size of 70 µm into a 15 ml Falcon tube and 10 ml of PBS were added. The 
samples were centrifuged at 400 g for 5 minutes and the supernatant was decanted. The cells were 
resuspended in 5 ml Nycodenz solution. 2 ml of FBS were carefully added to this solution under the 
formation of a phase boundary. The Nycodenz solution is a density gradient medium, allowing the 
separation of cells or subcellular organelles based on their relative density. In this case it was used to 
separate the denser kidney parenchymal cells and any remaining red blood cells from the less dense 
immune cells. The Nycodenz solution for this purpose was created using the ingredients in Table 13. 
The probes were centrifuged at 520 g for 20 minutes without using the brake. The immune cells formed 
a well-defined film between the Nycodenz and FBS phases. The majority of the kidney parenchyma 
cells remained as a pellet on the bottom of the falcon tube.  
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Table 13. Nycodenz solution ingredients 
Ingredient Amount  
NaCl 9.0 g 
TRIS 0.601 g 
KCl 0.227 g 
EDTA 0.112 g 
Nycodenz AG 33.55 g 
ddH2O 1220 ml 
 
The leukocyte film was transferred into a fresh 15 ml Falcon tube, resuspended in 10 ml PBS and 
centrifuged for 5 minutes at 300 g. The cell suspension was then resuspended in 0.5 to 1.0 ml of PBS 
and distributed to 5 ml polystyrene falcon tubes. Three 5 ml falcon FACS tubes were filled per sample. 
One was for an unstained flow cytometer analysis of cells. This analysis was done to determine the 
autofluorescence of cells in order to perform gating correctly. The second FACS tube was used for 
antibody staining. Counting beads were added to the third tube of each sample to determine the 
absolute number of cells in the sample. The cells in the second tube that were subsequently stained 
with fluorochrome-labeled antibodies were first incubated for 10 min with a zombie NIR dye, an APC-
CyTM7 DNA stain that is unable to penetrate an intact lipid bilayer, staining only DNA of dead cells with 
permeable cell membranes. The staining was carried out according to the manufacturer's instructions. 
After staining with zombie dye, 2 ml of FACS buffer were added to each tube. Table 14 shows the 
ingredients of FACS buffer. 
Table 14. Ingredients for FACS buffer 
Ingredient Amount 
Phosphate buffered saline (PBS) 500 ml 
Bovine serum albumin (BSA) 5 g 
Sodium azide 0.5 g 
 
The suspension was centrifuged at 400 g for 5 minutes. The supernatant was decanted, and the cells 
were resuspended in 2 ml FACS buffer. The cells meant for antibody staining were incubated with anti-
CD16 / CD32 (Fc receptor block) for 10 minutes according to the manufacturer’s instructions. The Fc 
receptor block was done to avoid unspecific, reverse binding of staining antibodies to the Fc receptor. 
The desired staining antibodies were then pipetted into the tube designated for staining and incubated 
for 40 minutes. The cells were then washed with 2 ml FACS buffer and centrifuged at 400 g for 5 
minutes. The supernatants were decanted, removing any unbound fluorochrome-labeled antibodies. 
The cells in the unstained tube and in the tube meant for fluorochrome staining were resuspended in 
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300 µl FACS buffer. The tube for cell counting was resuspended in 100 µl FACS buffer and shortly before 
measurement, 100 µl of counting beads solution (Life Technologies Corporation) was added. 
Compensation, counting, and measurement 
Compensation was done on the flow cytometer before measurement using compensation beads 
according to the manufacturer's instructions (AbCTM Anti-Rat / Hamster Bead Kit). This is a procedure 
that is important especially if many fluorochromes are used to stain one sample of cells. The 
fluorescence of the used fluorochrome can spill over and excite sensors measuring at other 
wavelengths. In compensating, one detects and corrects this spectral spillover and can therefore make 
more accurate assignments of emission signals to the labeled antibodies and thus to the surface 
markers. The sensitivity of the detectors for forward and sideward scatter was also adjusted before 
the measurement, allowing a more optimal assessment of the size and granularity of each measured 
cell. After these steps had been taken, a gating strategy was conceived using the labeled probes and 
the fluorochrome labeled cells were measured. Care was taken to ensure that at least 100,000 events 
were recorded whose forward and sideward scatter profile corresponds to that of immune cells. 
In the last and final step of measurement, the samples containing the counting beads were measured. 
The settings had to be adjusted for this measurement, as the counting beads had a higher signal of 
side scatter. Care was taken that at least 10,000 counting beads were analyzed by the flow cytometer. 
The counting bead solution contained the same amount of two different types of counting beads: A 
and B. These counting beads could be differentiated by the flow cytometer based on a difference in 
fluorescence properties. Both beads had to be counted at the same rate; if not, the suspension of cells 
and beads was not homogenous, and the result of the affected probe was not used in the final analysis. 
Since the quantity of counting beads per sample was known, the exact number of immune cells could 
be calculated. This in turn allowed the calculation of the quantity of each measured subtype of immune 
cell. The analysis of data was done using FlowJo software (Tree Star Inc.). 
3.5 Histological methods 
The preparation of histological samples described below as well as the histochemical staining were 
kindly carried out by Ms. Janina Mandelbaum and Mr. Dan Draganovici (medical technical assistants, 
Institute for Clinical Biochemistry, Medical Clinic and Polyclinic IV of the University of Munich). 
3.5.1 Formalin fixation and paraffin embedding 
As described in section 3.3.5, the middle pieces of the mouse kidneys were used to make histological 
samples. They were placed inside an embedding cassette and immediately stored in 4% formalin for a 
total of 24 hours to begin the fixation process. The embedding cassettes were then transferred into a 
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solution of 70% ethanol, where they remained for a minimum of 5 hours to a maximum of several 
days. Following this step, the sample was sequentially dehydrated in increasing concentrations of 
ethanol inside a carousel tissue embedding machine. After the treatment steps with increasing ethanol 
concentration were completed, the samples were treated in a xylol solution and later in a paraffin 
solution. The embedding cassettes were removed at the end of the dehydration protocol and 
embedded in the paraffin at a paraffin pouring station. Using a rotary microtome, the samples were 
then cut to 2 µm into a water bath. From this water bath, the cut samples were transferred to 
microscopy slides and dried overnight. The samples were then rehydrated using by performing the 
dehydration steps in reverse order. The slides were first placed into a xylol solution, then decreasing 
concentrations of ethanol and finally in distilled water. After the rehydration procedure, the slides 
were ready to be stained.  
3.5.2 Periodic acid-Schiff (PAS), Silver, a Sirius red staining 
PAS is a stain that is commonly used to stain kidney samples. It is sensitive in the detection of 
polysaccharides like glycogen and mucins like glycolipids and glycoproteins, giving these compounds a 
rich magenta color. The deparaffinated and rehydrated sample cuts were covered with 0.5% periodic 
acid for 5 minutes, washed with ddH2O and incubated for another 5 minutes with Schiff's reagent. 
Afterwards the stained slides were washed three times for 2 minutes in a 37°C water bath. A 
counterstain of hematoxylin was performed to stain the cell nuclei. For this, the slides containing the 
tissue samples were emerged in hematoxylin staining solution for 2 minutes. Afterwards the stained 
slides were washed for 5 minutes in warm water. The periodic acid oxidizes vicinal diols in 
polysaccharides or mucins creating a pair of aldehydes at the tips of the broken saccharide ring. These 
aldehydes then react with Schiff's reagent to form the magenta color. The hematoxylin nuclear 
counterstain works as a stain in a basic environment. The staining solution is kept in an acidic 
environment (pH 3-4). When the slides are emerged into the hematoxylin staining solution, the 
hematoxylin binds to the anionic phosphate groups within DNA. This binding is strong enough to 
withstand subsequent washing steps. The rise in pH (to around 7) by the washing with ddH2O causes 
the hematoxylin basic stain to turn violet-blue. 
The mouse kidney sections in this project were stained for fibrosis using a Sirius red stain. The 
deparaffinated and rehydrated sample cuts were stained with haematoxylin for 8 minutes, and then 
washed for 10 minutes in running tap water. The sections were then stained using Sirius red (Direct 
Red 80, Sigma) according to the manufacturers protocol.  
The Jones methenamine silver stain was used to stain human sections for fibrosis. This was performed 
as part of clinical routine at Nephropath as described in [176]. The silver stain used on the kidney 
sections for acute UA nephropathy was performed in our laboratory as previously described in [177]. 
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3.6 Statistical analysis 
The statistical analysis for the in vivo part of this project was performed using Microsoft Excel or 
GraphPad Prism. The data for the in vivo part of this project was shown as the arithmetic mean ± 
standard error of the mean (SEM). The Kolmogorov-Smirnov test was used to test the data for normal 
distribution. Student's t-test for independent samples was used for the comparison of two groups with 
normally distributed data. The one-way analysis of variance (one-way ANOVA) was performed if more 
than two normally distributed groups were statistically compared and Tukey's post-hoc test was used 
to determine the p-values of comparison between the groups. Non-normally distributed data was 
compared using the Wilcoxon-Mann-Whitney-test for two groups and the Kruskal–Wallis one-way 
analysis of variance with the Nemenyi post-hoc-test for three or more groups. The significance level, 
α, is the probability of falsely rejecting the null hypothesis for a statistical test and was set for this 
project at 5%. P-values below 0.05 were therefore considered statistically significant and in such cases, 
the null hypothesis was rejected. P-values above 0.05 were considered not statistically significant and 
the null hypothesis (no difference between the tested groups) was accepted. The following symbols 
were used in the graphs to dente different p-values: 
n.s. = not statistically significant 
* = p<0.05 
** = p<0.01  





4.1 Medullary gouty tophi associate with kidney fibrosis and tubular atrophy  
To answer the question whether medullary gouty tophi could be a cause for kidney function 
impairment, confirmation was first needed that gouty tophi associate with kidney damage in humans. 
Therefore, a histological case-report based study on the presence of kidney UA tophi in a large cohort 
of biopsy reports was performed, which has not been done before. The goal was not only to establish 
the relationship between gouty tophi and histological correlates for CKD such as glomerular and 
interstitial fibrosis, but also to characterize the cohort and to screen for histological finding that may 
be associated with medullary tophi that have previously not been described. In collaboration, the 
Arkana Laboratories database being the world largest collection of written kidney pathology reports 
was searched. In the first part of this study, a case-control study of these written biopsy reports was 
designed with the aim to investigate a potential association between kidney impairment and the 
occurrence of gouty tophi. 
 
4.1.1 Database search and biopsy prevalence of UA tophi 
At that time, the Arkana Laboratories database contained a total of 81,200 diagnostic kidney biopsy 
reports and was searched for “gouty tophi”. This search yielded a total of 84 biopsies in which the 
nephropathologist found gouty tophi. This made a total gouty tophus prevalence of 0.1% of all 
biopsies, meaning that 1 in 1000 kidney biopsies contained at least one visible UA tophus. To allow for 
an adequate statistical comparison and because of this relationship, the same database was searched 
for biopsy reports of other UA-related pathologies, namely hyperuricemia or hyperuricemia-associated 
conditions like gout. The reason for having a hyperuricemic control group is to take out the effect of 
hyperuricemia on observed differences. Hence, all observed differences between the groups must be 
related to UA tophi and cannot be due to hyperuricemia. The group of biopsy reports with 
hyperuricemia was very small (115 out of 81,200) compared to what would be expected out of such a 
large database. The reason behind this is that hyperuricemia had to be reported by the clinician to the 
nephropathologist together with other relevant clinical information related to the specific case. 
Preexisting hyperuricemia was often not deemed relevant information by the clinician and was 
therefore rarely reported. This fact, however, should not lead to any kind of group bias. To have a 
matching group size, 84 cases were selected at random of the 115 cases with other UA pathologies. 
Figure 11 provides an overview of the database search. Additionally, pictures and stained and 




the Arkana Laboratories. These were used for morphological characterization of the tophus and of 
related histopathological abnormalities. 
Arkana Laboratories Database:
81,200 biopsy reports
199 biopsy reports 
with UA related pathologies
Case group: 
84 biopsy reports of patients 
with gouty tophi Control group:
84 biopsy reports with 
hyperuricemia randomly selected
115 biopsy reports of patients 
with hyperuricemia
Search for UA related pathologies:
UA tophi seen in kidney pathology 
or hyperuricemia as reported by 
the clinician
Search for UA tophi
 
Figure 11. Database search synopsis.  
The database of Arkana Laboratories, consisting of a total of 81,200 at the time of search, was searched for biopsy 
reports with gouty tophi, hyperuricemia, gout, or UA urolithiasis. This search yielded a total of 199 biopsy reports. 
Of these, 84 reports contained gouty tophi, making up the case group. Of the remaining 115, 84 cases were 
selected at random to make up the control group of patients with other UA-related pathologies.  
 
 
4.1.2 Morphology features of human medullary gouty tophi 
Typical UA crystal granulomas were identified in all positive biopsies as shown in Figure 12. UA crystal 
granulomas are most commonly found in the kidney medulla. There are three characteristic layers of 
a tophus. UA crystals are needle-shaped and form the innermost layer of the tophus and often 
dissolved upon the fixation process (Figure 12a,c,d,g,h). In other cases the crystal masses remained 
intact and were visualized directly (Figure 12i), or using polarized light (Figure 12e,g). The UA crystal 
masses were surrounded by several epithelioid layers of mononuclear cells. Such inflammatory 
infiltrates consisted mostly of macrophages, some of which fused to create multinucleated giant cells. 




intracellular needle shaped clefts). The outmost layer, surrounding the inflammatory infiltrate consists 
of fibrosis and non-functional kidney interstitium. Figure 12g, a silver stain, shows the black stained 
fibrosis surrounding clefts and inflammatory infiltrates including multi-nucleated giant cells. Figure 12b 
and 12c show severely scarred medullary tissue with massive tubular atrophy and PAS-positive 
intratubular casts surrounding a kidney tophus. Figure 12h shows an aesthetically pleasing star-shaped 
medullary tophus with a massive surrounding inflammatory reaction. Figure 12i is a low power picture 
of the bioptic kidney cylinder containing a gouty tophus with undissolved crystals in the top right 
corner. 
 
Figure 12. Morphology of human gouty tophi in the kidney medulla. 
Hematoxylin and eosin (HE) stains were used in a, d, h, and i. Periodic acid-Schiff reaction (PAS stain) was used 
in b and c. Silver stain with a basis of hematoxylin and eosin was used in g. E and f show undissolved crystals 







4.1.3 Clinical characteristics and main pathological diagnoses 
On every pathology report, the age and gender of the patient was reported. Age (p=0.5, t-test) and 
gender (p=0.63, Fisher’s Exact Test) were similar in both groups (Table 15). Some, but not all, pathology 
reports contained information on the ethnicity of the patient. No comparison was made for Ethnicity 
due to the lack of Chi-squared distribution (Table 15).  
Table 15. Cohort characteristics. 
The age in the case group ranged from 16 to 83, with a mean of 52.3. The age in control group ranged from 9 to 
78 with a mean of 50.7. The data was compared using the test indicated in the right hand column.  
 
Descriptive Data   w/ Tophi  Control Total p= Test 
Age (years) 
 n=84 n=84 n=168 
0.5 t-test 
Range 16 to 83 9 to 78 9.0 to 85.0 
Mean 52.3 ± 16.5 50.7 ± 15.9 51.3 ± 16.2 
Sex 




Male 56 52 108 
Female 28 32 60 
Ethnicity 
White 26 26 52 
 
Black 6 13 19 
Hispanic 8 3 11 
Asian 5 3 8 
Native American 1 0 1 
Total 46 45 91 
 
The nephropathologist attributed the kidney damage in every biopsy to one or more main pathological 
diagnoses. These main pathological diagnoses were diabetic nephropathy (DN, 15.5%), 
arterionephrosclerosis (ANS, 28.6%), focal segmental glomerulosclerosis (FSGS, 31.5%), IgA 
nephropathy (IGA, 16.1%), acute tubular injury (ATI, 20.8%), lupus nephritis and other forms of 
glomerulonephritis (LN+GN, 13.7%), tubulointerstitial nephritis (TIN, 7.1%), lymphoproliferative 
related renal disease (LPRRD, 3.6%), thrombotic microangiopathy (TMA, 2.4%), and other pathologies 
(9.5%) (Figure 11). There was no distinction between primary and secondary FSGS. The differences in 
prevalence of the individual diagnoses between the groups were compared using Fisher’s Exact Test. 
Diabetic nephropathy (p=0.018) and acute tubular injury (p=0.022) were significantly less prevalent in 
the group with UA tophi than in the control group. Otherwise, the main pathological diagnoses were 
similar in both groups. No biopsy report carried solely the diagnosis ‘gouty nephropathy’. In all patients 
with medullary tophi, there was at least one other underlying main diagnosis. Often the biopsy reports 















































Main diagnoses Tophi Control Total p= 
n=84 n=84 n=168 
Diabetic nephropathy 8.3% 22.6% 15.5% 0.018 
Arterionephrosclerosis 29.8% 27.4% 28.6% 0.865 
Focal segmental glomerulosclerosis 36.9% 26.2% 31.5% 0.184 
Acute tubular injury 13.1% 28.6% 20.8% 0.022 
IgA Nephrophathy 16.7% 15.5% 16.1% 1 
Lupus nephritis and other glomerular diseases  13.1% 14.3% 13.7% 1 
Tubulointerstitial nephritis 3.6% 10.7% 7.1% 0.131 
Lymphoproliferative-related renal disease 4.8% 2.4% 3.6% 0.682 
Thrombotic microangiopathy 3.6% 1.2% 2.4% 0.62 
Other 9.5% 9.5% 9.5% 1 
 
Figure 13. Main pathological diagnoses 
In all biopsy reports, the nephropathologist gave one or more main pathological diagnosis. The most frequent 
diagnoses were arterionephrosclerosis (ANS), focal segmental glomerulosclerosis (FSGS), and acute tubular 
injury (ATI). The prevalence of each diagnosis was compared between the two groups in a 2x2 spread using 








4.1.4 Medullary gouty tophi associate with glomerulosclerosis and interstitial fibrosis 
In describing the kidney biopsy, the examining nephropathologist counted all visualized glomeruli 
including globally and segmentally sclerosed glomeruli. To approximate the ratio of glomerular lesions 
in the biopsied kidney, the number of globally sclerosed glomeruli visualized was divided by the total 
number of glomeruli visualized. Likewise, the total number of segmentally sclerosed glomeruli 
visualized was divided by the total number of glomeruli visualized to form the ratio of glomeruli with 
segmental lesions. Significantly more global glomerulosclerosis was found in the biopsies with gouty 
tophi than in the control group (Figure 14a). However, there was no difference in segmental lesions 
between the two groups (Figure 14b). Interstitial fibrosis was graded semi-quantitively by the 
nephropathologist, each biopsy received a score of none, mild, moderate, or severe interstitial fibrosis. 
Biopsies with gouty tophi were more likely to have moderate or severe interstitial fibrosis and less 
likely to have no or mild interstitial fibrosis than biopsies without tophi (Figure 14c). These findings 































































































Figure 14. Gouty tophi associate with kidney fibrosis.  
(a) The ratio (in percent) of global glomerulosclerosis was formed by dividing all globally sclerosed glomeruli by 
the total number of glomeruli visualized and multiplying by 100. The percent global glomerulosclerosis was 
compared using the Mann-Whitney-U test. (b) Similarly, the percent ratio of segmental sclerosis was formed by 
dividing all segmentally sclerosed glomeruli by the total number of glomeruli visualized and multiplying by 100. 
The two groups were also compared using the Mann-Whitney-U test. (c) Interstitial fibrosis was graded by the 
nephropathologist as none, mild, moderate, or severe. The distribution was compared on a 2x2 spread using 
Fisher’s Exact Test. The graph shows the distribution of each trait in percent of the total number of cases in each 










4.1.5 Gouty tophi associate with arteriosclerosis but not arteriolosclerosis 
The examining nephropathologist graded the severity of arteriosclerosis and arteriolosclerosis 
visualized on the biopsy as none, mild, moderate, or severe. Using the chi-squared test for trend, 
(Cochrane-Armittage trend test) the severity of arteriosclerosis and arteriolosclerosis between the two 
groups was compared. Biopsies with tophi contained more arteriosclerosis than biopsies without 
(Figure 15a). However, there was no difference in the severity of arteriolosclerosis (Figure 15b). These 















































Figure 15. Gouty tophi associate with macrovascular aging.  
The degree of arteriosclerosis (a) and arteriolosclerosis (b) was graded none, mild, moderate, or severe by the 
nephropathologist. The groups were compared using the chi-squared test for trend (Cochrane Armitage test for 
trend). The graphs show the distribution of severity as percent of the total number of biopsies in each group. n.s. 
= not statistically significant, *** = p<0.001. 
 
 
4.1.6 Gouty tophi associate with foot process effacement but not with GBM thickening 
On electron microscopy, the nephropathologist examined the severity of podocyte foot process 
effacement and thickness of the glomerular basement membrane. The severity of foot process 
effacement was also scored as none, mild, moderate, or severe. The glomerular basement membrane 
(GBM) thickness was measured and regarded either normal or thickened. There was significantly more 
podocyte foot process effacement in the gouty tophi group than in the control (Figure 16a). Foot 
process effacement is typical of proteinuric diseases such as FSGS, minimal change disease, IgA 
nephropathy, or diabetic nephropathy [178]. The rate of GBM thickening was similar in both groups as 
shown by Fisher’s exact test (Figure 16b). GBM thickening is an early change in kidneys of patients with 















































Figure 16. Foot process effacement and glomerular basement membrane thickening. 
The examining nephropathologist rated glomerular foot process effacement and GBM thickening viewed with 
electron microscopy as none, mild, moderate, or severe. The groups were compared using the chi-squared test 
for trend (Cochrane Armitage test for trend). The graphs show distribution of foot process effacement (a) or GBM 




4.1.7 Gouty tophi associate with proteinuria but not with increased serum creatinine  
Although the previous medical history of the patients was limited to the information that was given to 
the nephropathologist by the clinician, the serum creatinine (in mg/dl) and the amount of proteinuria 
(in g/day) was reported often enough for statistical comparison. Patients with gouty tophi (n=25) had 
significantly more proteinuria than patients in the control group (n=24) (Figure 17a). This fits to the 
finding of increased podocyte foot process effacement in the gouty tophi group. There was no 
significant difference in serum creatinine between patients with tophi (n=60) and the control group 









































Figure 17. Proteinuria and serum creatine at time of biopsy. 
The attending physician provided laboratory values of proteinuria (a.) and serum creatinine (b.) to the 
nephropathologist in many cases. The two groups were compared using the Mann-Whitney-U test. Box-and-
whisker plots show arithmetic mean, one standard deviation and range of data. n.s. = not statistically significant 
* = p<0.05 vs control cohort.  
 
 
4.2 Establishment of a new mouse model of UA nephropathy  
To further investigate the pathogenesis of chronic UA nephropathy and the relationship between 
medullary tophi and kidney atrophy, a suitable animal model is needed. The aim of the second part of 
the study was to establish an animal model capable of forming UA crystal deposits that resembles 
hyperuricemia-related UA crystalluria and chronic UA nephropathy. First, the previously established 
model of acute UA nephropathy in mice [168] was analyzed regarding its ability to induce chronic 
kidney changes like fibrosis, serving as a comparison with the later created model of chronic UA 
nephropathy.  
4.2.1 Uric acid crystalluria but no fibrosis or granuloma formation in mice with acute uric acid 
nephropathy  
One group of Alb-creERT2;Glut9lox/lox and one group of Glut9lox/lox mice were injected with tamoxifen 
as described in section 3.3.2. The mice were kept on standard chow diet for the entire duration of the 
experiment (45 days). Afterwards the mice received an inosine gavage of 100µg of inosine/day for 3 
days and were sacrificed on day 45. Alb-creERT2;Glut9lox/lox mice  that received inosine developed 
hyperuricemia and azotemia as indicated by a significant increase in serum UA (Figure 18a) as well as 
BUN (Figure 18b) and creatinine (Figure 18c) levels compared to the Glut9lox/lox control mice after 
inosine gavage on day 48. UA crystals were found in the urinary sediment of inosine-treated Alb-




frozen kidney sections showed precipitation of polarizable UA crystals inosine-treated Alb-
creERT2;Glut9lox/lox(Figure 18f and g), indicating that these mice developed crystalluria.  
 
 
Figure 18. Induction of hyperuricemia, crystalluria, and azotemia in mice with acute UA nephropathy 
Serum UA (a) serum BUN (b) and serum creatinine (c) were measured at day 0 (before Tamoxifen induction) and 
at days 7, 28, 42, and 45 of the experiment. In Alb-creERT2;Glut9lox/lox mice, a urinary precipitate is found (d and 
e). Within this precipitate, UA crystals were found upon microscopy of the urinary sediment (d and e). Polarizable 
UA crystals were found in the kidney parenchyma upon microscopy of frozen sections of Alb-creERT2;Glut9lox/lox 





Next, kidney sections were fixed, stained, and analyzed under a microscope. Figure 19 shows sample 
sections of both groups. Only mild changes related to AKI-like tubular dilation and injury were observed 
on PAS-stained kidney sections from inosine-treated Alb-creERT2;Glut9lox/lox mice (Figure 19b) 
compared to the control group (Figure 19a), which was in line with an increased mRNA expression of 
the kidney injury marker KIM-1 and the inflammation marker Tnfa and Il6 (Figure 19c).However, no 
fibrosis or UA tophi were observed in inosine-treated Alb-creERT2;Glut9lox/lox mice as indicated by silver 
stain (Figure 19d and e) as well as mRNA expression levels of the fibrosis marker fibronectin 1, Fsp1 
and Mmp9 (Figure 19f). The data indicate that short-term administration of inosine induced acute UA 
nephropathy associated with kidney injury and inflammation but without fibrosis and tophi formation.  
 
Figure 19. No tophus formation or fibrosis evident in acute UA nephropathy. 
(a-b) Kidney sections were fixed and stained using a PAS-Stain. (d-e) Corresponding kidney sections were stained 
using a fibrosis silver stain. (c and f) RT-qPCR was performed for KIM-1, Tnfα, Il6, Fibronectin 1, Fsp1, and Mmp9. 
n=5 mice per group. Data are mean ± SEM. ns = not statistically significant, * = p<0.05., 
 
4.2.2 Long-term exposure of Alb-creERT2;Glut9lox/lox mice to an acidogenic diet and inosine 
causes hyperuricemia with crystalluria and chronic uric acid nephropathy.  
In order to create a mouse model for chronic UA nephropathy, three experimental groups were used: 
1) Alb-creERT2;Glut9lox/lox mice that received tamoxifen injections and were placed on a ACD with 
inosine (Tam, ACD+Ino), 2) Alb-creERT2;Glut9lox/lox mice with tamoxifen injections and chow diet with 
inosine (Tam, Chow+Ino), and 3) Alb-creERT2;Glut9lox/lox mice with vehicle injections and ACD with 
inosine (Veh, ACD+Ino, as described in section 3.3.2). All three groups showed normal serum UA 
concentrations at around 5 mg/dl at week 0 (baseline). However, serum UA concentrations 
significantly increased in mice injected with tamoxifen and placed on a chow diet (Tam, Chow+Ino) or 




developed hyperuricemia compared to vehicle-treated mice (Veh, ACD+Ino). In addition, only 
tamoxifen-injected mice on a ACD diet (Tam, ACD+Ino) showed a significant increase in serum BUN 
levels (Figure 20b) and a significant diminished GFR (Figure 20c) over time compared to the other two 
groups. The data indicate that for Alb-creERT2;Glut9lox/lox mice to develop hyperuricemia and CKD, first 
tamoxifen is required to turn of Glut9, second inosine supplementation to induce hyperuricemia, and 
third an ACD with inosine to induce a decline in kidney function.    
 
 
Figure 20. Elevated UA, blood urea, and decreased GFR in tamoxifen-induced mice. 
At the end of weeks 0, 3 and 6, tail vein bleeds were collected from all mice. The serum concentrations of UA (a) 
and of BUN (b) were measured at these time-points. Similarly, transcutaneous measurement of GFR was 
performed at these timepoints (c). All groups were compared using a one-way ANOVA. P-values were calculated 
using Tukey’s post-hoc test. Differences between time points were calculated using a t-test. n.s. = not statistically 






4.2.3 Low urinary pH causes uric acid crystalluria in Alb-creERT2;Glut9lox/lox mice fed an 
acidogenic diet with inosine 
Reports have shown that a low urine pH promotes the crystallization of soluble UA and the 
development of UA crystal nephropathy [168]. To investigate whether urinary crystallization is 
responsible for the deteriorated kidney function in Alb-creERT2;Glut9lox/lox mice that were fed an ACD 
with inosine (Tam, ACD+Ino), the urine was checked in these mice. Indeed, light microscopy revealed 
crystal deposits in the urine of these mice after 6 weeks (Figure 21–before). Rasburicase, a clinically 
used recombinant uricase, which exclusively dissolves UA crystals, was added into the urine. The 
crystals completely dissolved in the presence of rasburicase after 5 minutes, confirming that the urine 
contains UA crystals (Figure 21). Whether the ACD contributes to tubular occlusion of UA crystals via 
lowering the urinary pH was tested using a pH electrode. As shown in Figure 22, Alb-creERT2;Glut9lox/lox 
mice that were fed an ACD showed a lower urinary pH than Alb-creERT2;Glut9lox/lox mice on a standard 
chow. Thus, an acidic urine pH contributes to the precipitation of soluble UA; therefore, UA crystal 
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Figure 21. Rasburicase completely dissolved urinary crystals confirming the composition of uric acid. 
Urine from a mouse of the tam, ACD group at week 6 was pipetted onto a glass microscope slide. A urinary crystal 
was focused under a microscope and the before picture was taken. Rasburicase (1µl) was added and pictures of 




























Figure 22. Lower urinary pH in mice fed an acidogenic diet. 
The urinary pH was measured at the end of week 6 using a microelectrode. The urinary pH was lower in the ACD 
with inosine fed mice compared with mice fed a standard chow diet. 
 
 
4.2.4 Hyperuricemia and uric acid crystalluria lead to macroscopically visible kidney remodeling 
After sacrifice, kidneys were checked for macroscopic abnormalities in hyperuricemic mice with 
crystalluria (Tam, ACD+Ino), mice with asymptomatic hyperuricemia without kidney impairment (Tam, 
Chow+Ino), or healthy mice (Veh, ACD+Ino). Kidneys from hyperuricemic mice with UA crystalluria 
were smaller in size and had a rough and pale cortex with white crystal deposits (Figure 23, left image), 
while the kidneys from the hyperuricemic as well as healthy group appeared both morphologically 
normal (Figure 23, middle and right image).  
Tam, ChowTam, ACD Vehicle, ACD
 
Figure 23. Macroscopic kidney morphology 
Immediately following mouse sacrifice, the kidneys were removed and freed of their fibrous capsule. 





4.2.5 Hyperuricemia with crystalluria induced kidney injury in Alb-creERT2;Glut9lox/lox mice  
To assess the extent of kidney injury between the three groups, total mRNA was isolated from the 
kidneys and RT-qPCR analysis for the kidney injury marker KIM-1 performed after 6 weeks (as described 
in section 3.4.1). As shown in Figure 24, mRNA expression levels for KIM-1 were significantly 
upregulated in hyperuricemic mice with crystalluria (Tam, ACD+Ino) compared with hyperuricemic 
mice (Tam, Chow+Ino) and healthy mice (Veh, ACD+Ino), indicating that hyperuricemia with UA 











































Figure 24. KIM-1 mRNA level is elevated in hyperuricemic mice with uric acid crystalluria. 
Total kidney mRNA from all three groups of mice (Tam, ACD+Ino; Tam, Chow+Ino; Veh, ACD+Ino) was isolated 
and RT-qPCR for KIM-1 performed (n=5 per group). The data was compared using a one-way ANOVA. P-values 
were calculated using Tukey’s post-hoc test. n.s. = not statistically significant, *** = p<0.001. 
 
4.2.6 Increased infiltration of immune cells and inflammation in mice with hyperuricemia and 
crystalline nephropathy 
CKD is not only associated with kidney injury but also with the infiltration of immune cells including 
macrophages, dendritic cells, neutrophils, monocytes, and T cells. To characterize the different 
immune cell population in more detail, flow cytometric analysis of single cell suspensions was 
performed as described in section 3.4.5. The kidney cells were stained with antibodies against CD45, 
CD11b, CD11C, F4/80. Figure 25a shows the gating strategy for CD45+ CD11b+ CD11c-F4/80high cells 
that were identified as macrophages, for CD45+ CD11b+ CD11c+ F4/80low cells that were identified as 
dendritic cells, and for CD45+ CD1b- CD11c- F4/80low cells that were classified as other immune cells. s 
Mice with hyperuricemia associated crystalline nephropathy (Tam, ACD+Ino) showed a significantly 




compared with hyperuricemic and healthy mice (Figure 25b and c). The same was the case for the 
subpopulation of CD45+ F4/80highCD11clow macrophages and CD45+ F4/80low CD11chigh dendritic cells 
(DCs) (Figure 25d-f). Corresponding to the functional data, no significant difference in the number of 







Figure 25. Increased macrophage and dendritic cell infiltration in hyperuricemic mice with uric acid 
crystalluria. 
After sacrifice (n=5 mice per group), a portion of the kidney was used to create a single cell suspension. These 
cells were fixed and stained with the aforementioned antibodies and analyzed using the gating strategy shown 
in a. CD45+ and F4/80low / F4/80high cells were gated in and further quantified in regard to their CD11b and CD11c 
status. (b and c) The number of CD45+ and F4/80low+high monocytic-derived cells per µl of single cell suspension 
in each group. (d) The number of CD45+ and F4/80high CD11clow subpopulation, corresponding to macrophages. 
(e) The number of CD45+ and F4/80low CD11chigh subpopulation, corresponding to DCs. (f) The number of CD45+ 
and F4/80high CD11c- subpopulation. All groups were compared using a one-way ANOVA. P-values were 




Furthermore, monocytes, neutrophils, NK cells, and T cells were also characterized in experimental 
kidneys by flow cytometry. The cells were stained with antibodies against CD45, CD11b, Ly6C, Ly6G, 
CD4, and CD8. Figure 26a shows the gating strategy. Similar as observed for the CD45+ F4/80high 
CD11clow macrophages and CD45+ F4/80low CD11chigh DCs,  the CD45+ CD11b- and CD11b+ cells (Figure 
26b and e) and their subpopulations were also significantly increased in hyperuricemic mice with 
crystalluria (Tam, ACD+Ino), while no significant differences were observed between the two control 
groups. This was also the case for the number of CD45+ CD11b+ Ly6C- Ly6G+ neutrophils (Figure 26c), 
CD45+ CD11b+ Ly6G- Ly6C+ monocytes (Figure 26d), and all CD45+ CD11b- T cells, including the CD4+ 
and CD8+ T cell subpopulations.  
To further quantify the extend of kidney inflammation, RT-qPCR was performed on kidney samples as 
described in section 3.4.1 using primers for Tnf-α and Il6. There was an increase in mRNA expression 
of Tnf-α (Figure 27a) and Il6 (Figure 27b) in the group with hyperuricemia and UA crystal nephropathy 
compared with the hyperuricemic or healthy group . No significant difference was observed between 
the hyperuricemic (Tam, Chow+Ino) and healthy (Veh, ACD+Ino) groups. Taken together, the mRNA 
data corresponded to the findings that were observed by flow cytometry showing that the kidney 








Figure 26. Neutrophils, monocytes and T cells infiltrate in high numbers in the kidneys of mice with 
hyperuricemia and uric acid crystalluria.  
Kidneys (n=5 per group) were prepared a described in section 3.4.5. (a) Gating strategy that was used to identify 
CD45+ CD11b- and CD11b+ cells. (b) The number of infiltrating CD45+ CD11b+ cells in the kidney. (c and d) The 
number of CD45+ CD11b+ Ly6C- Ly6G+ neutrophils (c) and CD45+ CD11b+ Ly6G- Ly6C+ monocytes (d). (e-g) The 
number of CD45+ CD11b- lymphocytes (e) and that of CD4+ T cells (f) and CD8+ T cells (g). All groups were 
compared using a one-way ANOVA. P-values were calculated using Tukey’s post-hoc test. n.s. = not statistically 


























































































Figure 27. Elevated expression of Tnf-α and Il6 mRNA levels in mice with hyperuricemia and 
crystalline UA nephropathy. 
(a and b) Total mRNA was isolated from kidneys of all three groups of mice after 6 weeks (n=5 per group) and 
RT-qPCR for Tnf-α (a) and Il-6 (b) performed. All groups were compared using a one-way ANOVA. P-values were 
calculated using Tukey’s post-hoc test. n.s = not statistically significant, *** = p<0.001. 
 
 
4.2.7 Formation of interstitial uric acid tophi and extensive fibrosis in hyperuricemic mice with 
crystalluria 
To investigate whether hyperuricemia and UA crystalluria contribute to interstitial fibrosis and induce 
the formation of UA tophi (UA crystal granulomas), kidneys from all three groups of mice were fixed 
and embedded in paraffin after sacrifice, and stained for PAS as described in section 3.5. Kidney 
sections from hyperuricemic mice with crystalluria (Tam, ACD+Ino) revealed massive tubular dilation 
and PAS-positive intratubular casts (Figure 28a, left), indicating acute tubular injury to  distal nephrons. 
No intratubular casts, tubular dilation, tubular atrophy, or fibrosis were observed in both control group 
(Figure 28a, middle and right). Furthermore, tubular atrophy and massive string-like broadening of the 
interstitium were present as sings of advanced chronic kidney fibrous conversion. Within the 
broadened fibrous interstitium, UA tophi were only observed with a small crystal cleft and surrounding 
inflammatory infiltrate in hyperuricemic mice with crystalluria (black arrows, Figure 28b), while UA 
crystal granulomas were absent in both control groups.  Of note, kidneys from healthy mice (Veh, 
ACD+Ino) did not show any signs of histological abnormalities, the corticomedullary junction with 
cylindrical tubular epithelium in the cortex appeared normal and the PAS-positive apical glycocalyx 
remained completely intact compared to the Tam, ACD+Ino group, suggesting that an ACD with inosine 
alone does not induce kidney damage in mice, where Glut9 is still active (Veh, ACD+Ino). 
To determine the extent of interstitial fibrosis, RT-qPCR was performed for the fibrosis markers 




all three fibrosis-related genes Col-1, Fibronectin 1, and FSP-1 in mice with hyperuricemia and UA 
crystal nephropathy (Tam, ACD+Ino) compared to the control groups. This is further evidence for 
fibrotic remodeling that was observed macroscopically (Figure 23) and microscopically (Figure 28a). 
Taken together, the data demonstrate that kidney UA tophi form as a result of UA crystal precipitation 
in an acidic urine leading to UA crystal-induced tubular injury, inflammation and interstitial fibrosis. 
Therefore, only hyperuricemia with UA crystalluria but not asymptomatic hyperuricemia causes CKD. 
 
Figure 28. Severe interstitial fibrosis and tophus formation in ACD fed hyperuricemic mice. 
(a and b) The kidneys were fixed in formalin and ethanol and later embedded in paraffin. The paraffin blocks 
were cut and stained using a PAS stain. Representative pictures of each experimental group were taken at 100x 
magnification. Black arrows indicate UA tophi. (c) Total mRNA expression levels of the fibrosis marker Col-1, 
Fibronectin 1, and FSP-1 (n=5 per group). All groups were compared using a one-way ANOVA. P-values were 





4.3 Asymptomatic hyperuricemia does not affect the progression of aristolochic acid-
induced chronic kidney disease 
That hyperuricemia with UA crystalluria but not asymptomatic hyperuricemia alone drives CKD with 
subsequent granulomatous interstitial nephritis has been demonstrated in section 4.2. However, 
whether asymptomatic hyperuricemia can contribute to the progression of pre-existing CKD has been 
subject of debate since many years due to the lack of experimental evidence, e.g. a suitable animal 
model of asymptomatic hyperuricemia with clinically relevant serum UA concentrations.  
4.3.1 Hyperuricemia does not alter the progression of aristolochic acid-induced chronic kidney 
disease 
To investigate whether asymptomatic hyperuricemia contributes to CKD progression, Alb-
creERT2;Glut9lox/lox and Glut9lox/lox control mice were injected with AAI to induce a progressive form of 
non-crystalline CKD or vehicle as control (as described in section 3.3.3). All three groups of mice were 
placed on a chow diet supplemented with inosine for 42 days. Serum was collected from mice at 
baseline and after 42 days to determine UA and BUN levels, and GFR measured. At baseline, serum UA 
levels ranged between 4-6 mg/dl in all three groups (Figure 29a). However, the serum UA levels 
significantly increased to 12-20 mg/dl in Alb-creERT2;Glut9lox/lox that were placed on a chow diet with 
inosine (group A – HU+CKD and group C – HU only), whereas Glut9lox/lox control mice had normal serum 
UA levels (group D – CKD only). This indicates that Alb-creERT2;Glut9lox/lox mice developed 
asymptomatic hyperuricemia as no crystals were found in the urine of these mice (group A and C). 
Furthermore, Alb-creERT2;Glut9lox/lox and Glut9lox/lox mice that received i.p. injections of AAI (groups A 
and B) were found to have significantly elevated BUN levels at day 42 compared to group C (Figure 
29b). In order to precisely assess the effect of asymptomatic hyperuricemia on kidney function, a 
transcutaneous GFR measurement using FITC-labeled sinistrin was performed as described in section 
3.3.5. GFR measurements were carried out at baseline, on day 21 and day 42 (Figure 29c). As expected 
and based on the BUN analysis, a diminished GFR was found in AAI-injected mice (group A and B), 
whereas no GFR decline was observed in mice with asymptomatic hyperuricemia only (group C). 
Importantly, no difference in GFR was found between mice with asymptomatic hyperuricemia and AAI-
induced CKD (group A) and mice with only AAI-induced CKD (group B) at either 21 days or 42 days 
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Figure 29. Asymptomatic hyperuricemia does not affect kidney function in aristolochic acid-induced 
nephropathy.  
Alb-creERT2;Glut9lox/lox and Glut9lox/lox control mice were injected with aristolochic acid I (AAI) to induce CKD or 
vehicle as control. All three groups of mice were placed on a chow diet with inosine for 42 days. (a and b) Serum 
uric acid (a) and BUN (b) in hyperuricemic mice with AAI-induced CKD (HU+CKD, group A), in mice with AAI-
induced CKD (CKD only, group B), and hyperuricemic mice without CKD (HU only, group C). (c) GFR was measured 
at baseline, day 21 and day 42 (n=5 mice per group). The data from day 42 was compared with a one-way ANOVA 
and the p-values were calculated using Tukey’s post-hoc test. n.s. = not statistically significant, ** = p<0.01. 
 
 
4.3.2 Asymptomatic hyperuricemia does not further aggravate tubular injury and fibrosis in 
mice with pre-existing chronic kidney disease  
Finally, tubular injury and interstitial fibrosis was evaluated in all three groups of mice. PAS staining 
showed similar severe signs of acute tubular injury, including extensive formation of PAS positive casts, 
flattening of tubular epithelium, dilatation and atrophy between both groups of mice with AAI-induced 
CKD (group A and B, Figure 30, top panel), while no injury was observed in mice with only 
hyperuricemia (group C, Figure 30, middle panel). In addition, Picro-sirius red staining was carried out 
to look at the extend of fibrosis. The Picro-sirius red staining revealed interstitial fibrosis in group A 
and B but not in group C (Figure 30, bottom panel). No UA tophus formation was observed in any group 
compared to previously noticed in Figure 28b. Thus, asymptomatic hyperuricemia does not affect the 






Figure 30. Asymptomatic hyperuricemia does not drive aristolochic acid I-induced chronic kidney 
disease nor uric acid tophi formation.   
Kidneys were fixed in formalin and ethanol and later embedded in paraffin. The paraffin blocks were cut and 







The relationship between UA and kidney function remains complex and is yet to be fully understood. 
The decline of kidney excretory function in CKD causes hyperuricemia [118] because UA is primarily 
excreted via the kidney. This raised the question whether hyperuricemia causes or accelerates CKD in 
a vicious cycle? If so, by what mechanism? 
It has been shown that acute hyperuricemia causes AKI as seen in patients with tumor lysis syndrome 
or crush syndrome [118, 181]. This is due to the supersaturation of UA, which leads to the precipitation 
of intratubular UA crystals causing tubular occlusion and acute tubular injury. However, the same has 
not been shown for chronic mild to moderate hyperuricemia, which is the most prevalent type of 
hyperuricemia [182]. If asymptomatic hyperuricemia worsens kidney function, one would recommend 
urate-lowering therapy. However, the current medical guidelines do not recommend treatment of 
asymptomatic hyperuricemia for patients with or without CKD [183] due the lack of large randomized 
controlled trails. 
Many authors, however, do imply a pathological role of hyperuricemia in CKD [121, 181, 184], citing 
various potential mechanisms. One such mechanism is UA crystal granuloma formation. As described 
in section 1.5.2, medullary UA crystal granulomas can occasionally be found in patients with advanced 
CKD and/or chronic gouty arthritis. For many years it was assumed that medullary UA crystal 
granulomas were a manifestation of chronic gout causing severe kidney function impairment [148, 
149] or a result of intratubular UA accumulation similar to acute UA nephropathy [152]. Later, several 
authors raised doubt about tophaceous nephropathy as a clinical entity and argued that current data 
could not prove that medullary UA crystal granulomas cause or contribute to CKD progression [147, 
153]. This resulted in the stagnation of the role of UA crystal granulomas [169]. However, many authors 
still list chronic UA nephropathy amongst causes for CKD [169]. In the present work, the relationship 
between asymptomatic hyperuricemia and UA crystal granuloma formation on CKD progression was 
examined. 
The objectives of this study were as follow: 
1. To characterize the histological abnormalities of diagnostic kidney biopsies with medullary UA 
crystal granulomas in a retrospective case-control study.  
2. To investigate whether hyperuricemia with UA crystal granuloma formation contributes to 




3. To test whether asymptomatic hyperuricemia exacerbates preexisting CKD in mice. 
5.1 Medullary UA crystal granulomas associate with histological signs of chronic kidney 
disease 
The objective of this retrospective case-control study was to determine the prevalence of UA crystal 
granulomas in diagnostic kidney biopsies and to investigate whether medullary granulomas associate 
with significant tissue atrophy and scaring. In this study, medullary UA crystal granulomas can be found 
in 1 out of 1,000 consecutive kidney biopsies (0.1%) and associate with foreign body granuloma 
formation and kidney atrophy and scarring.  
Hyperuricemia, gouty arthritis and urolithiasis have been shown to be associated with CKD [121, 150, 
185-187], and prior to UA lowering therapy the development of end-stage kidney disease was common 
in patients with gouty arthritis [188, 189]. In the mid-twentieth century, several attempts were made 
to specify the prevalence of kidney gouty tophi in kidney biopsies that were performed on living 
patients with impaired kidney function for diagnostic purposes or at autopsies, a body examination to 
determine the cause of death. For example, Sokoloff et al. reported 64 patients with gouty arthritis 
out of 80 cases of which five had UA nephropathy (6.25%) [190], and Murray et al. reported that 11 
out of 101 patients with interstitial nephritis had hyperuricemia as the primary cause of their kidney 
failure, presumably from chronic UA nephropathy (with kidney gouty tophi) [191]. In a larger study, 
Nickeleit et al. addressed the previously unknown prevalence of UA crystal granulomas in autopsies 
and found 37 cases with kidney UA deposits in a total number of 11,408 autopsies (classified as chronic 
UA nephropathy; 0.3%, other kidney comorbidities were not documented), and only three patients 
presented with chronic UA nephropathy from a selected group of 199 patients with end-stage kidney 
disease (1.5%) [153]. These authors concluded that in gouty arthritis patients, severe kidney damage 
with pronounced kidney dysfunction is almost invariably caused by other pathologies related to 
arterial hypertension, diabetes mellitus, urolithiasis or pyelonephritis [153]. Furthermore, in two 
consecutive studies the prevalence of medullary UA tophi was reported as 8-27% on autopsies from 
patients with preexisting CKD [151, 192]. The results of this large study with 81,200 total diagnostic 
kidney biopsies found medullary tophi at a frequency of 1 in 1,000 (0.1%) of all cases. While another 
retrospective study with only kidney biopsy reports from patients with predominant medullary tissue 
(796 of 7,409 total biopsies, 10.7%) found medullary UA crystal granulomas in 36 patients out of 572 
CKD patients (6.11%) [152]. 
To verify the concept that hyperuricemia-related medullary UA crystal granulomas would associate 
with histopathological signs of CKD progression and assuming that hyperuricemia and UA-related 
conditions are a prerequisite for UA crystal granulomas, while taking into consideration the fact that 




patients with medullary UA crystal granulomas were compared to biopsy reports of patients with 
hyperuricemia, and/or gout or UA urolithiasis but without medullary UA crystal granulomas. Therefore, 
eliminating the most prominent confounders for statistical comparison. In contrast to previous studies 
[151, 153, 192], the data now show that the observed histopathological differences cannot solely be 
explained by the kidney damage associated with pre-existing hyperuricemia, gouty arthritis or UA 
urolithiasis per se. The main pathological diagnoses were diverse, suggesting that UA crystal 
granulomas can occur in any type of CKD. Additionally, biopsies with medullary UA crystal granulomas 
had significantly more severe interstitial fibrosis, global glomerulosclerosis, foot process effacement, 
proteinuria, and arteriosclerosis.  
Three underlying mechanisms could be responsible for the observed association of medullary UA 
crystal granulomas and worsening interstitial fibrosis (Figure 31). One possible reason could be 
preexisting CKD with long-lasting hyperuricemia or gouty arthritis, which contributes to UA crystal 
deposition due to urine acidification, UA precipitation and concentrated UA in the urine triggering 
tubular obstruction and activation of the NLRP3 inflammasome assembly to secrete interleukin (IL)-1β 
[111, 194]. This in turn recruits more inflammatory leukocytes including macrophages that amplify a 
foreign body UA crystal granuloma reaction and interstitial fibrosis with tubular atrophy [195]. As a 
result of collecting duct obstruction and subsequent nephron loss the remaining undamaged nephrons 
must undergo hyperperfusion, which increases the risk for CKD progression. Second, it is possible that 
larger UA crystal masses induce a particular reparative process known as extratubulation via an active 
self-protecting mechanism similar to that observed for adenine crystal-induced nephropathy [196]. In 
this process, tubular cells and macrophages overgrow and surround crystals in the interstitium, 
restoring the tubular luminal patency, followed by degradation of interstitial crystals by granulomatous 
inflammation. Third, it is possible that interstitial fibrosis caused by an underlying kidney disease serves 
as a prerequisite for the deposition of interstitial UA crystals and is therefore a requirement for the 
formation of medullary UA crystal granulomas. This could suggest that granulomas exacerbate an 
underlying kidney disease in a vicious cycle of necroinflammation leading to further nephron loss, 
depending type of inflammation elicited by the tophus (Figure 31, possibility 3). So far, all reports are 
insufficient to establish causality. Whether medullary UA crystal granulomas cause kidney atrophy and 
CKD or whether previously established fibrosis is required for the formation of UA granuloma or both 







Figure 31. Possible mechanisms of medullary UA crystal granuloma formation. 
 
5.2 Hyperuricemia with UA crystal granulomas drives CKD progression in mice 
Thus far, no reliable mouse model of hyperuricemia with UA crystal granulomas has been described. 
Bluestone et al. reported crystal deposits in the kidneys of rats that were administered with oxonic 
acid and UA [161]. However, these animals did not develop hyperuricemia (serum UA < 5 mg/dl), the 
granuloma-like structures were inconsistent and only occurred in 66% of animals, and it is not clear 
whether the crystals are composed of UA. To overcome this issue, a novel animal model was 
established.  
Hyperuricemic mice can develop UA crystal-induced nephropathy if elevated UA levels (serum UA > 7 
mg/dl) persist for a long period of time [106, 107, 161]. This is due to a diminished capacity of the 
mouse kidney to handle large quantities of UA. The pathogenesis of this nephropathy is similar to the 
pathogenesis seen in humans with acute UA nephropathy due to tumor lysis or crush syndrome, where 
UA precipitates in the tubules and causes tubular occlusion and subsequent AKI. Consistent with the 




supplementation of ACD but short-term administration of the UA precursor inosine results in acute UA 
nephropathy in these mice without UA crystal granuloma formation [168]. An ACD is needed for the 
precipitation of UA crystals and the induction of crystalline nephropathy by lowering the urine pH 
[168]. While under chronic supplementation of ACD with inosine, Alb-creERT2;Glut9lox/lox mice develop 
hyperuricemia with serum UA levels in a clinical relevant range (12-20 mg/dL) as well as crystalline UA 
nephropathy with a decline in GFR (of approx. 80%). Crystalline UA nephropathy occurred as a 
consequence of intratubular crystallization of UA due to an acidic urinary pH, which causes tubular 
occlusion, tubular injury and inflammation (section 4.2). This inflammatory response was associated 
with the infiltration of immune cells including macrophages. In addition, Alb-creERT2;Glut9lox/lox mice 
with hyperuricemia and crystalluria had profound interstitial fibrosis and numerous UA crystal 
granulomas were also observed, a process that may contributes to CKD progression. In contrast, mice 
with asymptomatic hyperuricemia remained healthy.  
The fact that no UA crystal granulomas were found in mice with acute UA nephropathy but were 
present in mice with chronic UA nephropathy suggests that interstitial fibrosis is a prerequisite for 
tophi formation. Therefore, out of the three possible pathomechanisms of granuloma formation 
postulated in Figure 31, a combination of possibility one and three seems to be likely and would explain 
the data from the animal model because UA crystal granuloma formation requires preexisting 
interstitial fibrosis. Further support of this concept comes from the analysis of kidney biopsies. The 
association between tophi and glomerular and interstitial fibrosis on kidney biopsies is most likely 
caused by 1) vascular diseases as indicated by an increased arteriosclerosis score, or 2) advanced 
proteinuria-related diseases as shown by increased proteinuria and foot process effacement. Further 
support come from kidney biopsies of patients with AKI that showed significantly less UA crystal 
granulomas, indicating that UA crystal granulomas may primarily form in chronic kidney diseases. No 
biopsy report that was analyzed mentioned chronic UA crystal nephropathy as primary disease entity, 
suggesting that the kidney damage was always associated with another underlying primary kidney 
disease. Previous studies on this topic have shown similar results. For example, Nickeleit et al. 
concluded from an autopsy study with UA crystal granulomas that the “deterioration of kidney 
function can be better explained by other well-known risk factors of kidney disease most of the time” 
[153].  Berger and Yu, in a longitudinal study of gout patients with a 12 year follow-up, concluded that 
a decline in kidney function can be attributed to the development of “aging, kidney vascular disease, 
renal calculi with pyelonephritis or independently occurring nephropathy” [197]. In a follow-up study 
published seven years later, they showed that (articular) UA tophi were more likely to occur in patients 
with decreased kidney function and with the exception of a few patients that suffered “fulminant 
gout”, uncomplicated gout did not lead to the development of CKD [198]. CKD that did develop was 




with the clinical research, the in vivo mouse model in this study provides further evidence that 
preexisting fibrosis/CKD is required for UA crystal granuloma formation.  
Other underlying diseases including acute UA nephropathy as seen in Alb-creERT2;Glut9lox/lox mice and 
arterionephrosclerosis or FSGS in humans as shown in Figure 13 might serve as primary causes of CKD-
related fibrosis; therefore creating an environment for pH-dependent UA crystal precipitation, e.g. the 
intake of medications or dietary changes, followed by UA crystal-induced tubular injury and 
subsequent UA crystal granuloma formation, which in turn contributes to CKD progression. Patients 
with chronic gout can develop CKD in which the primary cause of kidney disease is often related to 
vascular complications [198]. In advanced CKD stages with persistent hyperuricemia, the possibility for 
the occurrences of kidney UA crystal granulomas increases, which would explain the strong correlation 
between UA crystal granulomas not only with kidney fibrosis but also with proteinuria, foot process 
effacement, and arteriosclerosis, which are all signs for advanced CKD. 
The deposition of crystals can elicit a foreign body reaction leading to mononuclear inflammation and 
formation of giant cells, similar to that observed in infectious or primary inflammatory granulomatous 
diseases including tuberculosis [199], sarcoidosis [200], granulomatosis with polyangiitis [201] or 
Chron’s disease [202]. If UA crystal granuloma formation augment the progression of CKD is 
immunological in nature, this would raise the question: Does the granulomatous inflammatory 
reaction surrounding the UA crystal mass exacerbate the cycle of necroinflammation, which is caused 
by the primary kidney disease that leads to fibrotic lesions in the first place? Further in vivo and in vitro 
studies are needed to resolve this question. UA tophi have been observed in joints, bones, ligaments, 
tendons, nerves, and the skin [203]. In joints, the presentation of tophi is associated with loss of 
articular function [204], known as advanced gout, which goes along with significant bone and cartilage 
destruction [90]. The UA tophus itself represents a complex inflammatory microenvironment with both 
pro-inflammatory and anti-inflammatory/pro-fibrotic responses [89]. For example, neutrophil 
extracellular traps (NETs) have been show to degrade inflammatory  cytokines and chemokines within 
the tophus using serine proteases [112]. Inflammation-mediated tissue destruction has been described 
many other granulomatous diseases as mentioned above as well as for pulmonary foreign body 
granulomatous reactions that can cause epithelial damage and fibrosis [205]. Therefore, it is 
reasonable to acknowledge that a certain destructive potential does emanate from the granulomatous 
inflammation surrounding the UA crystal mass in the kidney, and that the presence of such UA crystal 
granulomas amplifies the kidney damage in pre-existing CKD. Further in vivo studies in animal models 




5.3 Asymptomatic hyperuricemia does not contribute to CKD progression 
There is controversial debate about the role of asymptomatic hyperuricemia in prosperity diseases 
such as CVD, CKD, and hypertension. As discussed in section 1.4.2, the current dogma implies that 
soluble UA and hyperuricemia have both anti- and pro-oxidant properties in various diseases. In CKD, 
Johnson et al. published a review pointing towards a pathological role for asymptomatic hyperuricemia 
without crystalluria in the development of CKD [121] by causing endothelial dysfunction, RAAS 
activation, and vascular smooth muscle proliferation leading to arteriosclerosis, glomerular disease, 
metabolic syndrome, and CKD progression. The argumentation was primarily based on a report by 
Kahn et al. showing that oxonic acid-induced hyperuricemia in rats (serum UA 3.2 mg/dL) that had 
undergone 5/6 nephrectomy developed CKD [206], which resulted in kidney injury as a consequence 
of oxidative stress, hypertension and RAAS activation [121, 206]. Of note, although urate-lowering 
therapy with allopurinol was effective in improving kidney function [206], these authors did not 
provide evidence for the presence of UA crystals in the kidney or the urine. Therefore, it is unclear 
whether the kidney injury was due to asymptomatic hyperuricemia or hyperuricemia with crystalluria. 
Many other in vivo animal models investigating the effect of hyperuricemia have also been described, 
models that are either based on diet-, surgical- or chemical-induced mouse model of hyperuricemia 
including intraperitoneal injection of high concentrations of UA [207, 208], oral administration of 
potassium oxonate [209-211], unilateral ureter obstruction-induced nephropathy [212] or diabetic 
nephropathy [213], or on genetic modification of urate transporter [214]. All these studies reported 
that hyperuricemia causes kidney injury despite only very low serum UA levels (2-5 mg/dL), which 
would not even be considered clinically as hyperuricemia. Using a novel mouse model of asymptomatic 
hyperuricemia (serum UA 12-20 mg/dL) without crystalluria, the data within this thesis demonstrate 
for the first time that asymptomatic hyperuricemia does not cause CKD nor contributes to AAI-induced 
CKD progression. Further experimental evidence comes from a study by Preitner et al. reporting no 
sign of hypertension in mild hyperuricemic mice after 6 months [106]. In addition, a recent in vivo 
study also showed that asymptomatic hyperuricemia acts as suppressor of innate immunity with the 
ability to inhibit monocyte functions during acute gouty arthritis [215], which indicates a rather 
immunomodulatory role for asymptomatic hyperuricemia.   
In a recent review, Sato et al. performed an analysis of single- and multi-center randomized controlled 
trials (RCTs) on the topic of urate-lowering therapy in hyperuricemic patients with CKD [184]. The 
authors classified RCTs into “interpretable” and “non-interpretable” RCTs based on changes in GFR. 
The authors concluded that urate-lowering therapy is beneficial for a better outcome of kidney 
function and strongly recommended the use of urate-lowering therapy in patients with CKD and 
asymptomatic hyperuricemia. Unfortunately, the authors failed to correct for trial length in selecting 




recently corrected in a response meta-analysis [216]. This response letter pointed out other 
methodical flaws not only in the meta-analysis by Sato et al. but also in the underlying clinical trials 
and showed that the evidence from high powered, multi-center clinical trials has thus far refuted a 
beneficial role of urate-lowering therapy for hyperuricemic patients with CKD  [216]. Furthermore, two 
large multi-center RCTs recently published in the New England Journal of Medicine consistently 
reported no effect of urate-lowering therapy on GFR in patients with CKD and asymptomatic 
hyperuricemia [217] and no effect of urate-lowering therapy in patients with mild to moderate diabetic 
nephropathy secondary to type I diabetes [218]. Taken together, the in vivo data gathered in this 
project disprove any (non-crystal induced) effects of asymptomatic hyperuricemia on CDK progression, 
which in line with the clinical evidence. Therefore, asymptomatic hyperuricemia does not cause CKD 
nor contributes to the progression of CKD unless UA crystals precipitate in the kidney leading to UA 
crystal nephropathy.  
5.4 Limitations of this study 
One limitation of this study as well as by others is a potential underestimation of the true prevalence 
of medullary UA crystal granulomas on diagnostic kidney biopsies compared to autopsy studies 
because only patients with suspected kidney disease are subjected to a kidney biopsy and because of 
the sampling error in diagnostic biopsies. In general, not all diagnostic biopsies contain adequate 
sampling of medulla, and due to the focal nature of UA tophi, even predominantly medullary biopsies 
may occasionally miss the tophi. It is also important to note that although rare, medullary tophi have 
also been observed in diagnostic biopsies of patients without CKD (0.01%) [152] or a history of gout 
[151, 192]. One reason might be the handling of UA in kidney proximal tubules in patients with 
hereditary UA overproduction, as in asymptomatic hyperuricemia [185, 219]. Therefore, this 
retrospective case-control study does not prove a causal relation between UA crystal granulomas and 
CKD progression.  
The findings of this work are based on in vivo mouse models and the analysis of human kidney biopsy 
reports. Although, the animal model of hyperuricemia with or without UA crystal granuloma formation 
used herein is more closely related to the human disease setting and can be used as a translational 
model to investigate pathomechanisms, there are differences in the human and animal physiology 
because human diseases occur de novo, whereas animal disease models are produced artificially. In 
addition, due to the presence of functional uricase in lower mammals, rodents, especially rodent 
kidneys, have not evolved to deal high UA levels likes humans. This becomes evident when examining 
the Michaelis constant (Km) of kidney UA transporters in mice in comparison to humans as described 
in section 1.6. Human URAT1, for example with a Km of 370 µM has a higher affinity for UA than its 




Further evidence suggests that hyperuricemic mice or rats (serum UA level 2-5 mg/dL) develop kidney 
injury probably due to diet-induced acidification of the urine or genetic manipulation, which causes 
UA crystallization, similar to human acute gouty nephropathy [106, 107, 161]. Therefore, it is possible 
that mice are much more susceptible to crystalline nephropathy than humans because asymptomatic 
hyperuricemia does not lead to acute UA crystalline nephropathy in humans. In this study, care was 
taken that the conclusions drawn are correct despite this difference in UA handling between mice and 
humans and that the conclusions are therefore applicable to humans. However, other, perhaps yet 
unknown, mechanistic differences between human and rodent UA physiology and incorrect previous 
assumptions may have led to the drawing of incorrect conclusion.  
Currently, there is no specific staining available to identify UA crystal granulomas in this mouse model. 
Here, we identified UA crystal granulomas on PAS-stained kidney sections and quantified 
morphological abnormalities. UA crystals were also found in the urine of mice to confirm crystalluria. 
However, it is possible that some were incorrectly identified on kidney sections because during the 
fixation process, UA crystals will be dissolved and leave only empty clefts behind.  
5.5 Conclusions and future perspectives  
The research presented within this thesis highlights the effects of asymptomatic hyperuricemia and 
hyperuricemia with crystalluria in CKD, in particular the role of UA crystal granulomas on the 
progression of chronic UA crystal nephropathy. 
The precipitation of intraluminal UA crystals by feeding hyperuricemic Alb-creERT2;Glut9lox/lox mice an 
ACD with inosine triggers severe UA crystal-induced tubular injury and inflammation associated with 
the infiltration of immune cells such as macrophages, dendritic cells, neutrophils, monocytes and T 
cells. These inflammatory processes further lead to profound interstitial fibrosis and subsequent UA 
crystal granuloma formation. UA crystal granulomas form in the presence of preexisting CKD in a 
hyperuricemic environment and contribute to the progression of chronic UA crystal nephropathy. A 
proposed model is illustrated in Figure 32. Evidence for this finding comes from the retrospective case-
control study showing that the presence of medullary UA tophi in humans (prevalence of 0.1%) is 
associated with severe interstitial and glomerular fibrosis as well as arteriosclerosis and foot process 
effacement. Screening for intrarenal or postrenal UA crystal deposits could be a useful diagnostic tool 
in clinical practice, as demonstrated within this study, as to whether urate-lowering therapy e.g. with 
allopurinol or uricostatic drugs may be considered in hyperuricemic CKD patients.  
On the other hand, asymptomatic hyperuricemia without crystalluria does not cause tubular injury, 
inflammation and interstitial fibrosis and does not worsen signs of CKD compared to normouricemic 




beneficial effect on CKD progression [217, 218]. Whether a causal relationship between asymptomatic 
hyperuricemia and other diseases including metabolic syndrome and cardiovascular disease exists 
needs to be clarified in future studies.    
UA crystals induce kidney injury, inflammation and interstitial fibrosis, which ultimately leads to UA 
crystal granuloma formation and CKD progression. Hyperuricemic patients with incidentally found 
granulomas on kidney biopsy may profit from xanthine oxidase inhibition, which reduces crystal 
growth and thus reduces the inflammatory stimulus. Before such treatment recommendations are 
given, more studies, including human studies, are of course required. In addition, macrophages are 
known to contribute to the formation of granulomas, e.g. in lung tuberculosis and sarcoidosis [199, 
200]. The exact immune phenotype of kidney UA crystal granulomas in the fibrotic interstitium of 
humans and mice is subject of further investigation. The potential of UA crystal granulomas to amplify 
kidney damage needs to be further investigated to make adequate treatment recommendations for 
patients because patients with CKD profit from every nephron that can be saved. The investigational 
disinterest of recent years in chronic UA crystal nephropathy is unreasonable and much remains to be 
learned about UA tophi in the kidney and elsewhere in the body. This study has shed light on the 
pathogenesis of UA tophi, created a useful tool for their investigation, and will hopefully reignite 
interest in this forgotten disease. 
 
Figure 32. The pathogenesis of UA crystal-induced nephropathy. 
Hyperuricemia predisposes to the intraluminal deposition of UA crystals. These intratubular crystals induce 
kidney injury, leading to nephron loss and ultimately fibrosis. Within the fibrotic interstitium and after CKD has 
been established UA crystal deposition leads to the formation of UA granulomas, also known as UA tophi, likely 
further driving CKD and the progression of kidney fibrosis via inflammatory mechanisms. Edited after [220]. 
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